Medical Device ASIA, Jan-Feb 2016

Vol.8 No.1 | January-February 2016 | New Delhi

VITAMIN DEFICIENCY!

Health Care Reforms!

New Launch!

SOLED 15F LED Lamps!

Anemia & Hemoglobin Testing

! w Ne Rigel Ventrest 800

The Marathon health check from Metropolis!

Associatio ns Of

Hospitals!

MEDICAL FAIR ASIA

The Hall Mark Event FOR ASIA’S MEDICAL AND HEALTHCARE SECTOR

Y

Y

Y

Government of India, Registrar of Newspapers of India (RNI)#: DELENG/2009/30008

M

e d i t o r i a l

h i g h l i g h t s

Vol.8 No.1 | January-February 2016 | Annual Suscription: Rs.2,000 | Overseas: US$250

4

MEDICINE + SPORTS CONFERENCE ASIA

6

New Rigel Ventest 800

8

SOLED15-F - LED Lamps

10

EKF Diagnostics publishes ‘Anemia and Hemoglobin Testing’ guide

12

Did you Know Digesting Dal is not Easy

14

CPhI Istanbul Round Table Discussions with MENA Countries

16

International Medical Devices and Supplies Fair Ends

19

Era of advance technology in healthcare: Association of Hospitals

20

Primasil showcases latest innovative cooling cap at COMPAMED

21

Ready for the Change?

23

MEDICAL FAIR ASIA to host inaugural Asian edition of MEDICINE + SPORTS CONFERENCE in 2016

32

Taiwan Showcases Its Latest Innovative Products And Technologies

38

MEDICAL FAIR ASIA 2016

42

Obesity can lead to sever life threatening complications

46

Aptar Stelmi features PremiumCoat at CPhI India

48

7 out of every 10 Indians are Vitamin deficient: Metropolis Study

53

MACOR® Glass Ceramic: Enabling Medical Industry Innovation

Indian healthcare sector to grow to $280 billion by 2020: Report

India’s

healthcare sector is expected to be $280 billion in size by 2020, growing at a compound annual growth rate of 16 per cent, but it is in “dire need” of right policy framework and infrastructure push.With the healthcare industry seeing a robust growth trajectory, workforce in the sector is expected to be at 7.4 million in 2022. The overall Indian healthcare market today is worth US$ 100 billion and is expected to grow to US$ 280 billion by 2020, a compound annual growth rate (CAGR) of 22.9 per cent. Healthcare delivery, which includes hospitals, nursing homes and diagnostics centers, and pharmaceuticals, constitutes 65 per cent of the overall market. There is a significant scope for enhancing healthcare services considering that healthcare spending as a percentage of Gross Domestic Product (GDP) is rising. Rural India, which accounts for over 70 per cent of the population, is set to emerge as a potential demand source.

India requires 600,000 to 700,000 additional beds over the next five to six years, indicative of an investment opportunity of US$ 25-30 billion. Given this demand for capital, the number of transactions in the healthcare space is expected to witness an increase in near future. The average investment size by private equity funds in healthcare chains has already increased to US$ 20-30 million from US$ 5-15 million, as per PriceWaterHouseCoopers.

The Indian medical tourism industry is pegged at US$ 3 billion per annum,

with tourist arrivals estimated at 230,000. The Indian medical tourism industry is expected to reach US$ 6 billion by 2018, with the number of people arriving in the country for medical treatment set to double over the next four years. With greater number of hospitals getting accredited and receiving recognition, and greater awareness on the need to develop their quality to meet international standards, Kerala aims to become India’s healthcare hub in five years.

A unique initiative for healthcare ‘Sehat’ (Social Endeavour for Health and Telemedicine) has been launched at a government run common service centre (CSC) to empower rural citizens by providing access to information, knowledge, skills and other services in various sectors through the intervention of digital technologies and fulfilling the vision of a ‘Digital India’.

India and Sweden celebrated five years of Memorandum of Understanding (MoU). The cooperation in healthcare between India and Sweden will help in filling gaps in research and innovative technology to aid provisioning of quality healthcare.

India is a land full of opportunities for players in the medical devices industry. The country has also become one of the leading destinations for high-end diagnostic services with tremendous capital investment for advanced diagnostic facilities, thus catering to a greater proportion of population.

Medical Device ASIA | January-February 2016 | 3

MARK YOUR CALENDAR! 1 Sep 2016

MEDICINE + SPORTS CONFERENCE ASIA Marina Bay Sands ∙ Singapore

MEDICAL FAIR ASIA to host the inaugural edition of the MEDICINE + SPORTS CONFERENCE ASIA in 2016!

Organized by Navispace in cooperation with the Sports Medicine Association Singapore (SMAS), Exercise is Medicine Singapore (EiMS), FIMS (International Sports Medicine Association), WT Wearable Technologies and Messe Düsseldorf Asia; the MEDICINE + SPORTS CONFERENCE ASIA will bring together sports medicine experts, healthcare providers, physicians, fitness trainers and industry players from around the world to discuss innovations in sports medicine and pertinent healthcare challenges specific to Asia and the Southeast Asian region.

The conference is based on the MEDICA MEDICINE + SPORTS CONFERENCE that has been experiencing great success for three consecutive years and is part of MEDICA, the largest medical tradeshow in the world. As per its European equivalent, the first MEDICINE + SPORTS CONFERENCE ASIA, will be held in conjunction with a Messe Düsseldorf trademark event; MEDICAL FAIR ASIA. Similarly the two conferences are also built on the main objective of having an interdisciplinary exchange between international sports medicine experts, professional athletes, the sporting goods and healthcare industry.

In a global sports medicine market that is shifting towards Asia and is experiencing accelerated growth, the MEDICINE + SPORTS CONFERENCE’s Asian premiere comes at an opportune time to address some of the key factors that are driving this sector.

For one, population growth in the world’s most populous countries China and India constitute to sport related injuries of 5% in China and 3.8% in India. This is a key factor that drives the Asia Pacific Sports Medicine market which is growing at a CAGR of 6.96 % and is expected to be worth US$ 3.95 billion by the end of 2019.

At the same time in the developed Southeast Asian countries, ageing populations will develop much faster than in Europe and the US and see a total percentage increase of 430% by 2050 – the highest growth in Asia, which overall will be made up of 27% percent elderly population in 2050; coupled with an increased adoption of modern lifestyle habits and rapid economic growth in the Southeast Asia region, resulting in more noncommunicable diseases that amount to 62 % of all deaths across the regions, with more conditions such as heart and respiratory disease, osteoporosis, obesity, depression and type-2 diabetes being noted. This creates increased demands for healthcare services and immense pressure on the healthcare systems. In Singapore alone the health care expenditure is projected to reach SGD$12 billion by 2020.

The MEDICINE + SPORTS CONFERENCE ASIA will facilitate the right dialogue and networking platform for discussions and development of solutions. Attendees of the conference will be able to join in as eminent speakers from the industry will share on main topics such as physical 4 | January-February 2016 | Medical Device ASIA

activity as a key to disease prevention, defining health and fitness guidelines, creating the right activity programs for athletes and non-athletes, vital data and performance monitoring, digital systems in elite and recreational sports as well as new digital solutions such as new activity trackers, monitoring devices and other health gadgets that are emerging every day and continue to produce great investment potentials.

MEDICINE + SPORTS CONFERENCE ASIA | Program 10.00 a.m. OPENING KEYNOTE 10.30 a.m. SESSION 1

Exercise Medicine – The Role of Physical Activity in Healthcare 11.45 a.m. SESSION 2

Activity Program for Individual Needs 14.00 p.m. SESSION 3

Vital Data and Performance Monitoring 15.45 p.m. SESSION 4

Digital Systems in Elite and Recreational Sports

A Preview Of One Of the Distinguished Key Note Speakers Dr Ben Tan, BBM, PBM • MBBS (Singapore), MSpMed (Australia), FAMS (SpMed) • Designated Workplace Doctor (Compressed Air Works) Sports Physician • Chief, Department of Sports Medicine, Changi General Hospital • Senior Consultant, Changi Sports Medicine Centre • Senior Consultant, Singapore Sports Medicine Centre Dr Tan’s original research covers sports medicine and sports science, and has been published in international peer-reviewed journals and presented at international conferences. He is also the author of the books, “The Complete Introduction to Laser Racing,” and “Fight the Fat – What You Must Know and Do to Lose Weight,” and “Run for Your Life! – the Complete Marathon Guide.” Apart from sports injuries, Dr Tan’s areas of interest also include musculoskeletal sonography, extracorporeal shock wave therapy (ESWT), physical activity promotion, weight management, gait analysis, and performance enhancement.

MEDICAL FAIR ASIA

11th International Exhibition on Hospital, Diagnostic, Pharmaceutical, Medical & Rehabilitation Equipment & Supplies 31 Aug – 2 Sep 2016 Marina Bay Sands, Singapore Open for Booth Space Bookings at www.medicalfair-asia.com

NEW NEW

21x28.indd 1

08/02/16 11:43

New Rigel Ventest 800

For Accurate Verification Of Ventilator Performance

R

igel has extended its range of test instrumentation for biomedical equipment with the introduction of a specialist ventilator tester.

The Rigel VenTest 800 gas flow analyser is ideal for both bench top and field service testing of all commonly available ventilators to verify that the ongoing accuracy and reliability of the equipment remains within the required performance standards.

Precise sensor technology enables the VenTest 800 to accurately measure flow, pressure, temperature, and O2 concentrations bi-directionally and is compatible with 13 gas standards and 7 gas types.

The three model range includes a standard VenTest 800 analyser for use with all standard ventilators, including adult, neonatal, paediatric and high frequency equipment, as well as anaesthesia machines and spirometers. In addition, specially adapted models for the testing of vacuum measurements (VenTest 810) and low flow pressures (VenTest 820) are also available.

The VenTest 800 incorporates a simple, intuitive user interface and graphics display for ease of operation during testing and calibration settings.

As well as an internal memory, at the push of a button, all measured values can be transferred to PC records by USB, RS-232 and optional Ethernet interfaces. Once saved, optional software is available that provides a wide range of graphical analysis capabilities, including real time flow/pressure curves, functional zoom and certification documentation.

The Rigel VenTest 800 is the latest addition to the company’s comprehensive range of dedicated biomedical test equipment that also includes electrical safety analysers, vital signs simulators and performance analysers.

Details at www.rigelmedical.com/VenTest800 6 | January-February 2016 | Medical Device ASIA

Hearing Regulatory Updates regarding Registration Requirements, Labeling Requirements and Collaboration in China, ASEAN, Japan, Korea and other Asia Pacific Countries Analyzing the Cooperation and Challenges for Market Access Strategy and Distribution of Medical Device in Asia Pacific Region Understanding Supplier Chain Management on Process and Products Changes and Security Management throughout Managing Requirements and Strategies in Clinical Trials across the Asia Pacific Region Managing Quality Regulatory Compliance for Medical Device Enterprises and GMP Standards in Different Jurisdictions Sharing Future Trends of Medical Device with Drug and Health Economics Situation Current Status and Background of Medical Equipment Leasing and M&A in Medical Device Market Exploring the Best Platform for Experience Sharing and Networking Opportunities with Industry Peers and Experts

Contact Us Ms. Vivi Ye Tel: +86 21 5258 8005 * 8106 E-Mail: vivi.ye@duxes.cn Web: www.duxes-events.com/mdap2/

SOLED15–F Focusable LED lamp for examination and minor surgery

increasable up to 77.000 lux (small spot light beam) and a low power consumption (24 W).

The LEDs layout gives a visual comfort and produces a uniform, homogeneous and shadowless light.

SOLED15–F is the focusable LED examination light for diagnostics, minor surgery and universal applications.

It can be used for minor precision surgery, intensive care, recovery room, first aid, cosmetic surgery and dental sector. Soled15-F supplements the Starled Series range of lamps manufactured by ACEM Medical Company. SOLED15 – F contains all the advantages of LED technology and is suitable for multi purpose uses thanks to its flexibility.

It assures: • excellent light intensity • IR-free light beam • colour temperature (CCT) of 4.500°K • colour rendering index (CRI) of 95 • long life • low power consumption SOLED15-F grants a uniform distribution of light and can focus the light beam with a perfect illumination both on the surface and in depth providing the operator with the best working conditions.

The high technological level combined with the use of high-powered LEDs allow the lamp to have a very linear yield and a negligible performance decay for its entire life duration.

SOLED15-F has a light intensity of 50.000 Lux (large spot light beam) 8 | January-February 2016 | Medical Device ASIA

SOLED15-F has a round shape that makes it handy and functional both in use and move.

Its easy-to-move structure is suitable for diagnostics, test labs and dental surgery and its easy-to-grip removable and sterilizable handle makes it suitable even for critical sanitary applications.

SOLED15-F is provided with an I-Sense@ touch panel to control all the functions of the lamp: • ON/OFF • Light intensity adjustment • Light beam focusing This last function makes SOLED15-F particularly suitable for applications in the dental sector, minor surgery, gynecology where a focused and deep illumination is required.

SOLED15-F is available in the following versions: Ceiling mounted (single or double configuration) , Wall mounted, Trolley mounted (with ABPS battery on demand) For more information, please contact: ACEM SpA Medical Company Division Via della Tecnica 29 - 40050 Argelato Bologna – ITALY Ph +39 051 721844 Fax +39 051 721855 Email: info@acem.it Website: www.acem.it Medical Device ASIA | May-June 2015 | 15

EKF Diagnostics publishes

“Anemia and Hemoglobin Testing” guide

Detailed hematology guide available for free download hematology [3].

“As specialists in this area of POC testing, we have published this guide to share our knowledge and demonstrate our commitment to making blood donation and anemia screening easier, more affordable and more accessible than ever before,” said Katja Lemburg, EKF Diagnostics’ Global Product Manager for Hematology.

“Our diagnostic analyzers and tests deliver fast and reliable results for hemoglobin and hematocrit that provide both practitioner and patient with the information they need to make clinical or lifestyle decisions in seconds.”

E

KF Diagnostics, the global in vitro diagnostics company, announces the publication of its new guide, “Anemia and hemoglobin testing” [1].

Available to download for free from ekfdiagnostics.com, the in-depth hematology guide provides a review of the symptoms and causes of anemia, through to methods for testing hemoglobin and hematocrit, as well as factors that may influence these measurements.

Anemia is the most common blood disorder, affecting around 25% of the global population, and can be caused by poor nutrition or various diseases. It is a condition where the number of red blood cells or the availability of hemoglobin falls below the body’s physiological needs. Consequently, hemoglobin and hematocrit are the main blood tests used to diagnose anemia. In addition, pre-donation hemoglobin testing is an integral part of blood donor health assessment in many countries.

Since anemia reduces an individuals’ wellbeing,

10 | January-February 2016 | Medical Device ASIA

physical productivity and work performance, timely treatment can restore personal health and raise national productivity levels by as much as 20% in developing countries, as observed by WHO [2].

Notably, Anemia also contributes to 20% of all maternal deaths [2] , meaning that many countries conduct interventions during pregnancy to reduce anemia and its adverse effects.

Hemoglobin and hematocrit can be measured by a variety of methodologies. In particular, point-of-care (POC) testing in hematology has continued to grow in popularity; with hemoglobin measurement now the most commonly used parameter in POC

EKF’s range of hemoglobin analyzers includes Hemo Control, which uses the ‘gold standard’ azide methemoglobin method to deliver results from 25 seconds, and DiaSpect Tm, which uses a reagentless cuvette to provide results in just about one second. Its specialist hematocrit analyzer is the UltraCrit Plus which, uniquely, uses ultrasound to measure hematocrit with a high degree of accuracy within 30 seconds. HemataSTAT II is a microhematocrit centrifuge that provides quantitative readings for multiple samples that is perfect for laboratories or even veterinary use.

References: 1. http://workshop.fluidbook.com/view er/14091_4ce791664036d9927a1d9ba44bc7a5 af_1450197526/ 2. http://www.who.int/nutrition/topics/ ida/en/ Access date: 24/07/2015 3.

Where are we at with point-of-care testing in haematology? Briggs C et al., British Journal of Haematology, 2012, 158, 679-690.

For more information on EKF Diagnostics, please see www. ekfdiagnostics.com.

Did you Know Digesting Dal is not Easy

D

al and beans offer protein and tend to be sources of several minerals like potassium and magnesium. However, on the downside they offer only a moderate amount of protein. They contain 25% protein and approx 50% starch or high carbohydrate content, which explains why they’re so hard to digest. Also, beans are rich in protein and starch (requiring different digestive environments and enzymes) and this can make thorough digestion more difficult. While its protein is being digested, starch lies in the stomach and ferments, producing gas and toxins making one feel bloated and uneasy.

for stages of life leading to a better body composition and metabolic rate in modern sedentary lifestyles. Protein is much more satiating than both fat and carbs.”

If one were to get protein needs from dal alone you would have to consume a huge amount of dal and beans. The table below explains how long does dal in comparison to egg, chicken etc. takes to digest. I can safely say that, going by the merit of protein, eggs are easily available, digestible, affordable and, most importantly, cannot be adulterated. They contain one of the highest quality proteins found in nature.

Also, according to Dr Geeta Dharmatti, a nationally acclaimed nutritionist from Pune, “An egg as a whole has more nutrition than only egg whites or only egg yellow. The egg yellow (Yolk) has all the vital nutrients and half the protein of an egg. Studies recommend 1 whole egg daily for a healthy adult.

One egg contains 333 Mg of cholesterol which is equivalent to one day’s requirement. To outweigh the impact of cholesterol it is recommended to have more fiber in diet as fruits, vegetables and whole grains. Those who can, should add lean poultry because as little as 100gms of lean chicken per day will give nearly half the recommended protein intake your body needs. Lean Chicken, eggs whites, fish have less saturated fat than most red meat.”

Source: Poultry India

Dr Janaki Srinath, Nationally Acclaimed Nutritionist from Hyderabad very rightly said, “Given the risk low protein levels pose to the health of Indians, spreading proteins evenly across meals is extremely important. Combining vegetable, grain, pulses, egg and dairy products gives you a perfect protein intake for the day. Consumption of adequate protein ensures strong immune defense, efficient signaling of nerves and impulses, healthy hair and maintenance of fluid balance in the body. Protein can also turn into an energy provider when required by the body. Insufficiency of protein in the body affects all organs and overall growth and development. Probably the most important contribution of protein is its ability to reduce appetite and cause a spontaneous reduction in calorie intake. Protein intake is essential 12 | January-February 2016 | Medical Device ASIA

As digesting dal is not easy many experts recommend limiting its intake quantity for up to 50-60 grams per day. However, this gives you only 10-11 grams of protein per day which is much less than the recommended daily protein intake of 1 gram of protein for every kilogram of body weight every day, like Poultry India says in its nationwide Protein Awareness Campaign!

As governments struggle to increase the production of pulses, the poultry sector could well be the solution to India’s hunger problem. It’s no secret that eggs are one of the best sources of protein. What makes this even better is the high ratio of protein/fat that eggs offer, with a little more than 6 grams of protein and just 5 grams of fat. Most important, the eggs are as vegetarian as milk because they are unfertilized and can never be hatched.

The article has been written by Mr. Harish Garware, President of Indian Poultry Manufacturers Association and member of the Executive Advisory Committee, organizers of Poultry India.

CPhI Istanbul Round Table Discussions with MENA Countries

While opening its gates to exhibitors and visitors for new markets with the “Market Countries Investment and Business Opportunity Meetings” to be organized in Turkey for the first time, the largest pharmaceutical event in Eurasia, CPhI Istanbul 2016 also provides them the principles and strategies applicable for these markets.

Having become the common meeting point for the world’s giant pharma companies in a short time, CPhI Istanbul 2016 demonstrates once again that it’s not just an exhibition but is beyond it with the industry-specific events it organizes and the Turkey Pharma Industry Report 2016 which will first be announced in CPhI 2016.

14 | January-February 2016 | Medical Device ASIA

Organized by UBM EMEA (Istanbul), the world’s second largest pure play event organizer, CPhI Istanbul 2016 Pharmaceutical Event will be organized for the third time in Istanbul Congress Center on June 1st-3rd. Having the privilege of being Eurasia’s largest pharma event, CPhI Istanbul 2016 addresses major topics in the industry such as investment and business opportunities, legal regulations and policies, production, R&D, new technologies and supply chain and focuses further on new markets and the business potential therein with a conference within the organization.

Underlining that CPhI Istanbul 2016 creates major opportunities for accessing the pharma industry in Turkey, Middle East, North Africa, Middle Asia and Caucasia territories, Haluk Balcı, Chief Operating Officer of Turkey in UBM EMEA (Istanbul) said: “We are challenging the ordinary ways of doing an exhibition business and we continue to offer a special vision for our exhibitors and

visitors. We have designated the countries that will take part in the workshops we scheduled for this year with commissions of 3-4 persons as Jordan, United Arab Emirates, Morocco, Israel, Iran, Lebanon, Saudi Arabia, Egypt, Algeria and Turkey. We will accept our exhibitors and visitors to the country round table meetings to be held in the form of half an hour sessions in groups of 10 persons and we will provide them with strategic consultation services, particularly market intelligence”.

Mentioning that Turkey Pharma Industry Report 2016 which is prepared with the collaboration of Fortune Turkey, one of the most prestigious economy magazines in the world will be announced in CPhI Istanbul 2016 for the first time again, Haluk Balcı said: “Fingers are crossed for Turkey Pharma Industry Report 2016 as the report keeps its finger on the pulse of the pharma industry and steers its development. Our report contains findings regarding Turkey’s pharma industry and data to guide and offer solutions for every kind of

needs of local and foreign players who would like to take part in this large market”.

Highlighted topics in the conference program are “Positioning Turkey as the Global Pharma Production Center by Building It On Entrepreneurship, Innovation and R&D Operations”, “Evaluation of Changing Dynamics in the Market: How to Be Strong Against the Main Issues We Are Facing in the Pharma Industry Today?”, “Becoming Stronger in the MENA Region Using Investment Strategies and Effective Growth: Project and Portfolio Management”, “Middle East and North Africa as the Hot Domain of the Large Pharma Industry: New Production Facilities that Rivet the Developing Market Status in the Region”.

It is expected that top level executives from leading players of the countries in the region, scientists and academicians from university communities,

senior representatives from state organizations and institutions, officials from industry-specific associations and foundations as well as investment experts, analysts and consultants will attend the conference as speakers and share their opinions via case study evaluations, panel discussions and common presentations.

CPhI Istanbul 2016 is organized

by UBM EMEA (Istanbul) with the support of the Turkish Republic Ministry of Health, Turkish Drug and Medical Devices Agency (TİTCK) and Small and Medium Enterprises Development Organization (KOSGEB) in official partnership with the Pharmaceuticals Manufacturers Association of Turkey (İEİS). Also, Nobel İlaç assumed the platinum sponsorship, Deva İlaç the diamond sponsorship and outdoor cladding, Helba İlaç, BD Medical Pharma and CCCMPHIE the gold sponsorship, Koçak Farma, Pharmactive, Vem İlaç and Infa Group the silver sponsorship,

Analitik Kimya has undertaken the web site events and routing, Mustafa Nevzat has undertaken the nametag, Şanlı İlaç has undertaken the door entrances, BD Medical Pharma assumed the register area sponsorships and Infoset, Harman Finochem, Nosch Labs PVT, Pharma Action, Softi Gel Procaps, Symbiotica and Promo Pharma assumed the other sponsorships.

About UBM EMEA (Istanbul): Headquartered in London, UBM is a London-listed global leading fair organization business with offices in more than 40 countries and over 5,500 employees. It is the world’s second largest pure play event organizer. It is a member of the FTSE 250 index with over 450 events a year. In addition to traditional exhibition business, the company attaches great importance to technology and content and is a leading company that ensures each exhibition raises the bar in the industry each year. For detailed information: www.ubm.com.

Medical Device ASIA | January-February 2016 | 15

“The sixth Hong Kong International Medical Devices and Supplies Fair (Medical Fair 2015) ended, having welcomed nearly 10,000 buyers over the three-day fair period, up 3.6 per cent year-on-year. Organised by the Hong Kong Trade Development Council (HKTDC) and co-organised by the Hong Kong Medical and Healthcare Device Industries Association, the fair saw encouraging growth in buyer attendance from Asia as well as strong interest in products targeting the silver market.”

International Medical Devices and Supplies Fair Ends NEARLY 10,000 BUYERS; STRONG DEMAND FOR ELDERLY CARE PRODUCTS wheelchairs and medical devices for elderly care and rehabilitation, from different countries. The CEO of the company, Jan Býma, said he had shortlisted five potential suppliers from the Chinese mainland, Taiwan and Korea. “Products that we are interested to source include: wheelchairs that help users stand up, foldable wheelchairs, walking aids as well as bathtubs and toilet seats for the elderly. Our initial orders are estimated at US$30,000 to US$50,000.” He said the fair showcased a broad range of products and was a good place for sourcing.

B

uyers from Japan, Taiwan, Singapore, and Vietnam recorded significant growth. It is an indication of Asia’s strong demand for medical supplies and services,” said HKTDC Deputy Executive Director Benjamin Chau. “An ageing population and increased health consciousness are also factors boosting the demand for healthcare equipment in the region.

Silver Market According to the United Nations, it is estimated that there would be two billion people aged 60 or above by 2050, accounting for 21 per cent of the world’s total population. Reflecting this trend, many buyers attended the fair to source rehabilitation products and those targeting the silver market.

Australia’s Comfort Mobility Pty Ltd. is a manufacturer of medical fixtures and supplier of healthcare equipment for the elderly. The company’s Director, 16 | January-February 2016 | Medical Device ASIA

John Minchenberg, said: “This is our first visit to the Medical Fair. We’ve found a potential supplier from Hong Kong for electrical wheelchairs. We will have further discussions with them on pricing and other details. If everything goes smoothly, we could see four to six containers worth of business a year.”

First-time Czech buyer Meyra Cr s.r.o. is a producer of sports and electrical wheelchairs. The company also sources a range of traditional

Lin Chin Hsing, Manager of Taiwan’s Silver Care Health Management Consultants Ltd., was optimistic about business prospects for medical equipment and products for the elderly in Taiwan. He attended the fair to look for more product choices. “The HKTDC’s business matching service is very useful. I am already in contact with several Hong Kong and Chinese mainland suppliers for different products, such as a stair-climbing wheelchair, electrical wheelchair, and a pain-relieving device for women in labour. The visit has been very rewarding.”

Boai Enterprise Group (China) operates nearly 100 hospitals and medical institutions offering general

and specialist services. Zhu Juhong, Assistant to the President of the Group, said the fair had helped them learn more about the latest technologies and products, and that initial contacts had been made with several potential suppliers from Hong Kong, Singapore and Canada.

Product Launch The Medical Fair is an important platform for many manufacturers and suppliers to promote their latest medical technology and products to overseas buyers. The fair welcomed a record of more than 250 exhibitors from 11 countries and regions this year. ID Infinity Ltd. showcased its dental floss tool, Toothbat, as well as its latest WOW and Childers series. Director Gordon Lam said the response they received had exceeded earlier expectations.

“A lot of buyers have expressed interest in our products; we have sold all 500 sets of products in less than two days. We are now taking pre-orders. Aside from Hong Kong buyers, we have also established ties with buyers from the Chinese mainland, Japan, Costa Rica, India, Korea, Thailand and Australia. Some of them even expressed interest in becoming our distributors.” Mr Lam said he would continue to exhibit at the Medical Fair to promote the brand and launch new products.

First-time exhibitor Active Fun Company Limited used the fair to introduce its trampoline which promotes exercise and mobility among the elderly. Product Manager Cyrille Guillot said the fair was useful for promoting the benefits of rebound therapy. “Buyers from different places have been very interested in our products. If we were to offer our products for sale, we would have sold over 100 units already. We will be discussing longterm cooperation with our new contacts.”

Hong Kong Science and Technology Parks’ tenant Deltason Medical Limited showcased the Rex Bionics robotic device, which it distributed at the fair. The device uses advanced robotic technology to help spine cord injury (SCI) patients to stand up and walk around. Service Engineer Pete Witherspoon said: “The Medical Fair is an excellent trading platform for us to meet buyers from around the world and explore opportunities. We have promoted and demonstrated the robotic device at the fair and got a good response from many visitors. A Hong Kong buyer even offered to place an order immediately.”

Regional Pavilions Foster Trading This year’s Medical Fair featured two

inaugural pavilions: the Canada Pavilion and the Taiwan Medical and Biotech Industry Association Pavilion. The Canada Pavilion comprised 11 companies, showcasing medical solutions and health management products and technology. Cynthia Carlone, Vice Consul & Trade Commissioner of the Consulate General of Canada in Hong Kong and Macau, said the fair offered a great chance for Canadian companies to explore the Hong Kong market and expand their presence in the Asia-Pacific region. “We have met many buyers on the first day, and we are optimistic that our companies will find the right trading partners here,” Ms Carlone said.

Taiwan Medical and Biotech Industry Association’s Chief Secretary, Sidney Lin, said Taiwan’s medical industry has been expanding steadily over the years. The Association set up its inaugural fair pavilion to help its members develop their presence in the international market. “A number of buyers have expressed interest in our products. Several potential customers from the Chinese mainland and the UK have even examined some of our devices in depth, and we hope to develop business with them,” Mr Lin said.

To help industry professionals gather market intelligence, the HKTDC organised a number of seminars during the fair, inviting industry experts to discuss topics such as the latest medical technology, regulations and market trends. The concurrent Hospital Authority Convention 2015, one of the region’s largest healthcare conferences, welcomed more than 5,000 healthcare professionals this year, and created strong synergy with the Medical Fair. ❖ Medical Device ASIA | January-February 2016 | 17

Stylish Fusion of Design and Hygiene

Kaldewei presents its New Wash Basins that are Aesthetically Hygienic

E

very year, well over half a million patients in hospitals contract infections caused by germs. The wash areas in patient and treatment rooms and in areas accessible to the public pose a particularly high risk of infection.

Wash areas therefore should be made of a material with an unbeatable hygienic surface that is easy to clean and leaves behind not the slightest trace of germs or bacteria.

Kaldewei steel enamel has proven superior here for decades, with clear material advantages that benefit such areas as the hospital bathroom.

Kaldewei has now added wash basins to its portfolio of prolific bath products to provide health centers and hospitals with the ideal solution to its hygiene needs.

The new wash basins from Kaldewei are available in five model series for use in a wide variety of areas – from patient bathroom and treatment room through to public washrooms for visitors. With up to five installation options – from undercounter, builtin and inset countertop or countertop styles through to wallhung washbasins – they suit any installation situation. For optimal use, for example by patients in wheelchairs and invalid chairs, the washbasins can be mounted flexibly at the required height. With the new wash basins made of steel enamel, Kaldewei offers the optimal solution for the design of hospital wash areas. The pore-free surface is provided with the Kaldewei easyclean finish as a standard, ensuring that water and dirt simply roll off the steel enamel surface and not even the tiniest scratches occur despite

years of daily use and cleaning, leaving nowhere for germs or bacteria to settle.

Kaldewei demonstrates its expertise as a partner in the fit-out of hospital wash areas with resilient, durable and exceptionally hygienic product solutions made of steel enamel.

Introducing the new wash basin segment means that bathroom designers are now able to plan a beautifully coordinated patient bathroom – from the shower and bathtub through to the wash area – made completely of a single, superior material supplied by a brand manufacturer. This unique quality is backed by Kaldewei with a 30-year guarantee on all its wash basins made of steel enamel.

About Kaldewei Franz Kaldewei GmbH & Co. KG is a worldwide partner for iconic bathroom solutions shaped from superior steel enamel. With a portfolio of over 500 shower surfaces, bathtubs and washbasins, the premium manufacturer provides perfectly coordinated solutions for project business and private clients – featuring a uniform material throughout and harmonious design Kaldewei steel enamel products have demonstrated their distinctive material advantages in the bathroom over decades. The company has been recognised as a “Brand of the Century” and, thanks to its collaboration with internationally renowned design companies, has received over 100 design awards. Founded in 1918, Kaldewei is now represented in more than 70 countries around the world, either by its own subsidiaries or by sales partners.

18 | January-February 2016 | Medical Device ASIA

Era of advance technology in healthcare: Association of Hospitals

I

nnovations and technological developments in 2015 have taken India’s healthcare sector to new heights. The members of the Association of Hospitals (AOH) assembled at Bombay Hospital in Mumbai today amidst anticipation over the innovative healthcare solutions emerging from India.

Known as the pioneers of Mumbai’s healthcare, AOH overviewed the growth in the past year and previewed expected developments in the sector.

The nation has made tremendous improvement on various fronts and is healthier today than ever. Despite this evolution the struggle continues with critical issues and gaps in the healthcare system. Dr. P.M. Bhujang, President of the Association of Hospitals said, “India has successfully eradicated many diseases, including smallpox, polio and guinea worm disease.

The country has significantly reduced HIV infections and AIDSrelated deaths. Additionally, India has emerged as a hub for genericdrug manufacturing and as a result public infrastructure has developed a lot in last year still utilization is not maximize. There is need for awareness and join coordination between government, hospitals and medical practitioners.”

Mr. Gautam Khanna, Vice President of the Association of Hospitals added, “Spending on healthcare in India was estimated five percent of

gross domestic product (GDP) in 2013 and is expected to remain at that level through 2016. Total healthcare spending in localcurrency is projected to rise at an annual rate of over 12 percent, from an estimated $96.3 billion in 2013 to $195.7 billion in 2018. While this rapid growth rate will reflect high inflation, it will also be driven by increasing public and private expenditures on health.”

Further, Dr. Rajkumar Choudhary Hon. Secretary with the Association of Hospitals commented, “In 2015, we have witnessed a number of innovations with joint efforts by government and private enterprise.

For example, the number of cadaver donations has increased in Mumbai compared to earlier years. Also, the usage of a green corridor was never done before and this is an example of the advanced technology supported by government.”

Mr. N. Santhanam, Vice President of the Association of Hospitals added, “We have 52 member hospitals and we have nine thousand three hundred beds where all the sections of society receive equal medical services. The technological advancements and skilled doctors of our member hospitals have played a major role in contributing to the growth of the healthcare sector especially in Mumbai.

Dr. Tarang Gianchandani, Hon. Treasurer of the Association of Hospitals further said, “As per the predictive scenario of India healthcare system for the next financial year , there is a target for development of 50 technologies and more dedicated for the treatment of diseases like Cancer and Tuberculosis.

In today’s time hospitals are not only using using Robots for complicated surgeries and MRGFus for cancer treatment but also high end diagnostics in nuclear medicine such as PET CT for early and accurate diagnosis of cancer . New technology are being utilized for early detection of tuberculosis.

Indian pharmaceutical companies too have substantially stepped up investments in R&D during 2014-15 and have spent almost seven per cent of their consolidated net sales on it . This would surely help to soon have New medication in Indian markets and this exponential growth will overcome international market in times to come . These new drugs

will help to reduce cost of healthcare to patients" About Association of Hospital: The Association of Hospitals has been formed under the Memorandum dated August 6, 1985 and is registered under the Societies Registration Act, 1860. The Association is also registered under Bombay Public Trust Act, 1950 as Public Charitable Trust with the office of Charity Commissioner, Maharashtra State.

Presently there are 52 members of the Association and all of them are Public Charitable Trust Hospitals registered under Bombay Public Trust Act, 1950 with the concerned offices of Charity Commissioner, Maharashtra State depending upon the Jurisdiction.

The members being not-for-profit charitable hospitals render yeomen service to the public and bear a major share of all the public burden of rendering healthcare to the people.

We will continue to give our best efforts in coming years to make India fully equipped and skilled.”

Medical Device ASIA | January-February 2016 | 19

Primasil showcases latest innovative cooling cap at COMPAMED

P

rimasil Silicones is showcasing its new cooling cap, devel oped in collaboration with The University of Huddersfield for Paxman™, at COMPAMED, the leading international market place for the medical supplier industry and product development, in Dusseldorf on 16-19th November 2015.

The Paxman cooling cap is designed to bring relief to chemotherapy patients by reducing the risk of hairloss during treatment. It consists of a compact refrigeration system connected to a lightweight silicone rubber cap. By lowering the head and scalp temperature, immediately before, after and during chemotherapy treatment, blood flow to the hair follicles is reduced which prevents or minimises damage.

silicone profile and tubes, silicone calendered strip and silicone sheets.

Silicone rubber is a proven material for many medical sector products such as: tubing, tourniquets, liver slings, mats and inserts for surgical trays, duckbills and conical seals.

“Silicone rubber is a remarkable material which is flexible in every sense of the word. Through subtle alterations of its chemistry we can bend and shape its properties to meet most needs, and when the right minds are brought together our potential for creating, improving and transforming medical devices is almost limitless,” Caroline Herdman, Medical Division Manager, Primasil Silicones.

“COMPAMED provides a great forum

The cap was first developed in the 1990s, however recent innovation is designed to enhance the effectiveness and availability of the cooling cap. The main challenge was to create a new silicone rubber formulation that would give the reusable cap greater flexibility to adapt to varying head shapes and sizes around the world. In addition, the partners looked at ways of increasing automation in the cap’s production to satisfy rising demand for the product.

Visitors to COMPAMED will also be able to learn how Primasil’s wider capabilities in silicone rubber for the medical sector are making a difference to medical devices. The team will be there to discuss applications using Liquid Silicone Rubber (LSR) and High Consistency Rubber (HCR) mouldings, extruded 20 | January-February 2016 | Medical Device ASIA

to share ideas and expertise with visitors, often leading onto key collaborations for the development of innovative products”, Caroline concludes.

For further information on Primasil Silicones’ products and services visit www.primasil.com To register to attend COMPAMED visit: www.compamed-tradefair.com About Primasil Silicones An impressive track record for creating innovative and perfectly tailored solutions has made Primasil Silicones Europe’s leading independent manufacturer of silicone and organic rubber products. Customers are assured that all materials formulated will meet their precise

business requirements. Materials can be supplied for use in the customer’s own manufacturing process or converted into finished products using Primasil’s extensive moulding and extrusion plant.

Working across industries, worldwide, Primasil’s market-leading expertise is combined with its exceptional quality and service standards, facilities and flexibility to deliver the latest silicone technology and the perfect fit. www.primasil.com Images: For more information please contact: Sharon Smith Clear B2B Marketing & PR Ltd Tel +44 (0)1285 626000 s.smith@clearb2b.com

Ready for the Change? – PTI Provides Guidance on New EU Clinical Trial Regulation PTI prepares clinical trial and regulatory professionals for smooth transition to the new regulation with a live and accessible webinar e-course

The EU-CTR replaces the EU Clinical Trials Directive and is designed to improve harmonisation on conducting clinical trials of medicinal products for human use throughout the EU.

Adriaan Fruijtier

P

harmaceutical Training International (PTI), the leading supplier of online and public event-based training courses for the pharma, biotech and medical device sectors, is providing detailed guidance on the new EU Clinical Trial Regulation (EU-CTR) which applies from 28th May 2016. Making sure clinical trial and regulatory affairs professionals are up-to-date and prepared, PTI is hosting a convenient and cost-effective 2-hour webinar e-course at 2:30 PM (UK) on Wednesday 2nd December. Industry expert Adriaan Fruijtier – Director Regulatory Affairs, CATS Consultants GmbH, and formerly Head of the Oncology Group within Global Regulatory Affairs at Bayer AG and Bayer Corporation - will host this event.

It brings with it significant procedural changes for both trial authorisation and conduct for which individuals and organisations must be prepared. In PTI’s webinar e-course titled ‘Guidance on the New Clinical Trial Regulation’ Adriaan Fruijtier will provide a comprehensive examination of the new regulation. He will cover the scope, authorisation procedures, low intervention clinical trials, the EU portal and database, transparency requirements, key timelines and milestones, and a helpful comparison between the new regulation and the existing directive. With over 20 years’ experience in pharma regulatory affairs, Adriaan will also be available

for a valuable live question and answer session at the end of the webinar. “This really is essential information for anyone working in clinical trials and regulatory affairs,” said PTI’s Managing Director, Rosie Bernard. “With this webinar e-course we wanted to make it as easy as possible for professionals to access the most up-to-date and useful guidance to ensure a smooth transition to the EU-CTR next year.

Adriaan is an expert with a great deal of experience in pharma regulatory affairs, ranging from the European Medicines Agency to the likes of Glaxo and Novartis, so I can’t think of anyone better placed to deliver this guidance. It’s also a great opportunity for professionals to address specific queries with him personally in the live Q&A session.”

www.pti-global.co.uk/. Follow PTI on twitter @PTI_Courses for realtime updates and insights.

Be prepared for the new EU-CTR. Learn more and register for this webinar e-course. For more information, please visit http://

Pharmaceutical Training International +44 (0)20 7017 7000 registration@pti-global.co.uk http://www.pti-global.co.uk/

About PTI PTI is a global interactive training partner committed to the personal progression of aspiring life science professionals. PTI provides multidiscipline and company-wide training solutions to the global pharmaceutical community. Based in London, UK, PTI has an expanding assortment of courses specifically tailored to the (bio)pharma and medical device industries which range in method from distance learning to tailored on-site training and include interactive game-based learning modules. For more information, visit http://www.ptiglobal.co.uk/.

Medical Device ASIA | January-February 2016 | 21

VERSEON PRESENTS DATA ON A NEW CLASS OF ANTI-COAGULANTS “AT THE 8TH BIOTECH SHOWCASE CONFERENCE”

D

r. David Kita, Verseon’s cofounder and Vice President of Research and Development, presented preclinical data on the company’s new class of anticoagulants at the 8th annual Biotech Showcase yesterday - January 12th.

Kita’s presentation included recently obtained data on a number of drug candidates in this new class that demonstrates continuing and steady progress in Verseon’s anticoagulation program.“ “Verseon is a technology-based pharmaceutical company that uses their own proprietary and patented computational drug discovery platform to research and develop novel drugs and drug therapies for unmet medical needs.“ “The Company’s

new class of oral, highly selective, direct thrombin inhibitors have been proven in preclinical efficacy studies and also show pharmacokinetic profiles suitable for oral dosing.

Verseon’s compounds demonstrate reduced risk of major bleeding relative to current novel oral anticoagulants (NOACs).“ “Kita said, “the data we have obtained in our anticoagulant program represents comprehensive preclinical, scientific evidence that Verseon’s compounds have lower bleeding risk than conventional therapies with equivalent or better therapeutic potential. This data will form an important part of our upcoming IND (Investigational New

22 | January-February 2016 | Medical Device ASIA

Drug) filings for this program.”

“Forward-Looking Statements:“This press release contains forwardlooking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise

required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forwardlooking statements as a result of the impact of a number of factors.“ Verseon is a pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics for today’s challenging diseases.

The Company is applying its platform to a growing drug pipeline and has three active drug programs in the areas of anticoagulation, diabetic macular edema, and solid tumor cancers. www.verseon.com

MEDICAL FAIR ASIA to host inaugural Asian edition of MEDICINE + SPORTS CONFERENCE in 2016 ✓ First ever MEDICINE + SPORTS CONFERENCE ASIA to feature greater focus on Southeast Asia, bringing together sports medicine experts, healthcare providers, physicians, fitness trainers and industry players to discuss innovations in sports medicine and pertinent healthcare challenges in the region ✓ To be held on 1 Sep 2016 during MEDICAL FAIR ASIA 2016 at a new venue, the Marina Bay Sands Singapore

T

he MEDICAL FAIR ASIA, Southeast Asia’s most definitive event for the medical and healthcare industry, will host the first ever Asian edition of the MEDICINE + SPORTS CONFERENCE in 2016.

The inaugural MEDICINE + SPORTS CONFERENCE ASIA will be held on 1 September 2016 during MEDICAL FAIR ASIA 2016 at a new venue, the Sands Expo & Convention Center, Marina Bay Sands Singapore. The conference is jointly organized by Messe Düsseldorf Asia and Navispace AG, with the support from founding cooperation partners namely; Sports Medical Association Singapore (SMAS), Exercise is Medicine Singapore (EiMS), FIMS (International Sports Medicine Association) and WT Wearable Technologies Group.

Founded in 2013 at the largest medical trade show MEDICA, the internationally established MEDICINE + SPORTS CONFERENCE has repetitively attracted great speakers and high-level attendees from around the world. The inaugural Asian edition will feature eminent speakers on topics such as physical activity as a key to disease prevention, defining health and fitness guidelines, creating the right activity programs for athletes and nonathletes, vital data and performance

monitoring, digital systems in elite and recreational sports as well as new digital solutions such as new activity trackers, monitoring devices and other health gadgets.

The conference also aims to feature a greater focus on the pertinent healthcare challenges in the Southeast Asia region, using the opportunity provided by MEDICAL FAIR ASIA, with relevant industry participation and attendance of quality trade buyers and decision makers, to generate high-level exchanges and discussions.

The established MEDICINE + SPORTS CONFERENCE has been brought to Asia in view of the booming sports medicine market in this region. According to market research solution ReportLinker, the Asia Pacific sports medicine market is estimated to grow at a compound annual growth rate (CAGR) of 6.96% and is expected to reach US$3.85 billion by the end of 2019.

At the same time, with the rapid economic development and increasing adoption of modern lifestyle habits in Southeast Asia, rising non-communicable diseases like cardiovascular diseases, chronic respiratory diseases, and diabetes have become one of the major healthcare challenges in the region.

According to the World Health Organization (WHO), 62% of all deaths in the region are due to noncommunicable diseases and 48% of affected persons are aged below 70 years.

Mr Gernot Ringling, Managing Director of Messe Düsseldorf Asia, said: “Over the years, we have seen sports medicine advance by leaps and bounds worldwide, making it important for stakeholders and industry players in this region to remain at the forefront of the latest innovations and to address the most

prominent healthcare challenges. I am very excited for Messe Düsseldorf Asia to partner with Navispace AG in bringing MEDICINE + SPORTS CONFERENCE to Asia for the first time. This will enhance the experience of all our delegates at MEDICAL FAIR ASIA 2016 and add significant value to the event.

MEDICAL FAIR ASIA is proud to host the inaugural Asian edition of MEDICINE + SPORTS CONFERENCE.” “It is most appropriate and timely that we base the Asian edition of MEDICINE + SPORTS CONFERENCE at MEDICAL FAIR ASIA, the hallmark event for Asia’s medical and healthcare sector,” said Dr Sonja Sulzmaier, Managing Partner of Navispace AG. “Healthcare investment and the emphasis on sports medicine are shifting towards Asia, particularly in the Southeast Asia region.

It is imperative to facilitate the right dialogue and networking platform to discuss how technology and innovation in this sector can help address some of the region’s healthcare challenges. We are confident that this inaugural conference will deliver valuable opportunities for discussions and development of solutions to meet the challenges of the fast changing healthcare landscape in this region.”

MEDICAL FAIR ASIA 2016, organized

by Messe Düsseldorf Asia, will be held from 31 August to 2 September 2016 at a new venue, the Sands Expo & Convention Center, Marina Bay Sands Singapore.

As a testament to the significance of the event for the medical and healthcare industry, 1,000 exhibitors from 45 countries, 20 national pavilion and country groups and 15,000 qualified trade buyers and decision makers are expected to participate in this 11th edition.

The 3rd edition of MEDICAL MANUFACTURING ASIA in 2016 will also co-locate with MEDICAL FAIR ASIA 2016 to offer synergistic opportunities for specialists sourcing diversified solutions for the healthcare and medtech industries.

Focused on the medical technology and medical manufacturing sector, MEDICAL MANUFACTURING ASIA is jointly organized by Messe Düsseldorf Asia and the Singapore Precision Engineering & Technology Association (SPETA).

About MEDICAL FAIR ASIA 2016 Organized by Messe Düsseldorf Asia, MEDICAL FAIR ASIA is part of the ”World of MEDICA” brand and has established itself as the region’s leading international exhibition on hospital, diagnostic, pharmaceutical, medical & rehabilitation equipment & supplies. Following its successful growth path since its inception in 1997, MEDICAL FAIR ASIA acts as the gateway to Asia for global industry players by providing the perfect platform to showcase the latest industry innovations, to network and do business.

For more information, please visit www.medicalfair-asia.com About Messe Düsseldorf Asia Messe Düsseldorf Asia is a subsidiary of Messe Düsseldorf in Germany, one of the world’s leading trade fair organisers, responsible for organising more than 20 global No. 1 exhibitions in various industries including medicine and health, specifically MEDICA, COMPAMED and REHACARE INTERNATIONAL held in Düsseldorf, Germany. With extensive expertise in organising trade fairs in Southeast Asia, Messe Düsseldorf Asia has developed a portfolio of numerous trade fairs in the region since 1995.

For more information, please visit www.messe-duesseldorf.de/MDA

Medical Device ASIA | January-February 2016 | 23

Haydon Kerk Motion Solutions Adds New WGS Compact Integrated Screw/Slide System to 24-Hour Express Store

H

aydon Kerk Motion Solutions recently added the WGS Wide Guide Screw to its linear slide product line.

Now, the WGS can be ordered from the Haydon Kerk e-commerce website with orders shipped within 24 hours www.haydonkerkexpress.com Made from the same quality components as used in the RGS® Linear Rail Series, the WGS Linear Slide utilizes a screw-driven carriage that offers reliable, continuous linear speed, while maintaining accurate positioning. Length and speed of the WGS are not limited by critical screw speed, allowing high RPM, linear speed and long stroke lengths.

The WGS slide has a unique, compact profile that provides improved torsional stiffness and stability versus Haydon Kerk’s existing RGS and RGW slide products. Stroke options of 6”, 12” and 18” are available in three different leads (0.1”, 0.5” and 1.0”) for 24-hour delivery at the Haydon Kerk e-commerce store. Each WGS Slide ships with a size 17 and a size 23 motor mount.

speeds of more than 60 inches per second (1.5 meters per second) that rival belts and cables, while offering superior positioning accuracy, repeatability, axial stiffness and lower maintenance costs.

Longer lengths and different leads are available on a special order basis. An integral mounting base can provide support over the entire length that can extend up to 8 feet (2.4 meters).

The WGS utilizes sliding plane bearings on a low-profile aluminum guide rail that keeps the motion smooth throughout the travel distance. The lead-screw is precision made of high-quality stainless steel rolled on site at a Haydon Kerk manufacturing facility.

All moving surfaces include Kerkite® high-performance polymers running on a Kerkote® TFE coating. The

Information on other available imperial and metric leads is available at www.haydonkerk.com. These include short leads for nonbackdriving vertical applications, eliminating the need for brakes, as well as longer leads capable of 24 | January-February 2016 | Medical Device ASIA

slides come with wear-compensating, anti-backlash driven carriages.

Additional driven or passive carriages can be added, along with application-specific customization.

Linear guides without the drive screw also are available.

For more information about Haydon Kerk products, contact: Haydon Kerk Motion Solutions, 1500 Meriden Road, Waterbury, CT 06705.

Telephone: (toll free) 800-243-2715 and (international) +1- 203-7567441. Fax: 203-756-8724. E-mail: info.haydonkerk@ametek.com.

Web site: www.haydonkerk.com About Haydon Kerk Motion Solutions, Inc. Haydon Kerk Motion Solutions is a business unit of AMETEK, Inc., a leading global manufacturer of

electronic instruments and electromechanical devices with annual sales of $4.0 billion.

Haydon Kerk Motion Solutions is the joining of two world-class brands in the field of linear motion: Haydon Switch and Instrument, Inc. and Kerk Motion Products, Inc. Together as Haydon Kerk Motion Solutions, they offer a wide range of highperformance and precision linear motion products. Recognized as a leading manufacturer of stepper motor-based linear actuators, rotary motors, lead screw assemblies, and linear rail and guide systems used in niche market applications, Haydon Kerk Motion Solutions has developed industry-renowned brands built upon its technical innovation, versatility, customization, product durability, and dedicated customer service.

HAYDON KERK MOTION SOLUTIONS RELEASES 2016 LINEAR MOTION CATALOG AND DESIGN GUIDE

H

aydon Kerk Motion Solutions, a brand of AMETEK® Precision Motion Control, announces the release of its new Catalog and Design Guide, revised for 2016. The new Haydon Kerk catalog has been updated and expanded with new product sections, including the WGS06 linear rail, the brushless IDEA servo motor controllers, Size 8 double stack 21000 linear actuators, ZBM micro screw nuts and 15mm external linear Can-Stack actuators.

The new 260+ page catalog and design guide illustrates a wide range of products engineered for use as building blocks in sophisticated linear motion assemblies depending on the customers’ application needs. The catalog is a “starting point” to help explain Haydon Kerk technology, products and core capabilities. Customers are invited to work directly with Haydon Kerk’s engineering team to customize components or to integrate them into a unique motion assembly.

handling equipment used in laboratory automation; transport stations and valves in semiconductor manufacturing equipment; and inspection, test, dispensing and 3D printing equipment used in industrial automation, camera, lighting, projectors, antenna drives and numerous other high-tech precision motion systems.

Kerk Motion Solutions, 1500 Meriden Road, Waterbury, CT 06705.

Telephone: (toll free) 800-243-2715 and (international) +1- 203-7567441. Fax: 203-756-8724. E-mail: info.haydonkerk@ametek.com.

Web site: www.haydonkerk.com

To receive the 2016 catalog and design guide, visit the Haydon Kerk “Ask the Expert” tab http:// www.haydonkerk.com/ AsktheExperts/tabid/388/ Default.aspx to request a printed copy. Just check the new Haydon Kerk Catalog box and give us your contact details.

Haydon Kerk Motion Solutions is a business unit of AMETEK, Inc., a leading global manufacturer of electronic instruments and electromechanical devices with annual sales of $4.0 billion.

For more information about Haydon Kerk products, contact: Haydon

About Haydon Kerk Motion Solutions, Inc.

Haydon Kerk Motion Solutions, they offer a wide range of highperformance and precision linear motion products.

Recognized as a leading manufacturer of stepper motor-based linear actuators, rotary motors, lead screw assemblies, and linear rail and guide systems used in niche market applications, Haydon Kerk Motion Solutions has developed industryrenowned brands built upon its technical innovation, versatility, customization, product durability, and dedicated customer service.

Haydon Kerk Motion Solutions is the joining of two world-class brands in the field of linear motion: Haydon Switch and Instrument, Inc. and Kerk Motion Products, Inc. Together as

The catalog is divided into 3 major sections: 1) Precision lead screw and nut assemblies; 2) Linear actuators and stepper motor drives; and 3) Motorized and nonmotorized linear rail systems. In addition to basic product information, each section includes a brief overview of the technology behind the products, part number construction, sizing charts, and product comparison charts.

Typical applications for Haydon Kerk products include robotics, infusion pumps in medical equipment; liquid Medical Device ASIA | January-February 2016 | 25

Novel EKF biomarker identifies people likely to develop Diabetic Nephropathy

N

ew data paves way for adoption of sTNFR1 as a routine test for Diabetic Nephropathy management EKF Diagnostics, the global in vitro diagnostics company, announces that new data has been presented in support of soluble Tumour Necrosis Factor Receptor 1 (sTNFR1) as a biomarker to predict progression of Diabetic Nephropathy (also referred to as Diabetic Kidney Disease).

This new data [1] was recently presented at Kidney Week, the world’s premier nephrology meeting, organised by the American Society for Nephrology (ASN) and is now available to view online at EKF Diagnostics’ website www.ekfdiagnostics.com/ stnfr1.html.

The study from the Joslin Diabetes Center, one of the world’s leading diabetes research institutes, includes sTNFR1 data on 1335 patients followed over a four to six year period.

This study was part funded by EKF and is co-authored by EKF Diagnostics, Pfizer, Eli Lilly and leading researchers from the Joslin Diabetes Center. The data clearly highlights the role that sTNFR1 can play in identifying diabetic patients for inclusion in clinical trials of novel therapeutic interventions to prevent or delay progression to End Stage Renal Disease (ESRD).

The current practice of clinical trial

recruitment is typically limited to patients with high levels of urinary albumin excretion (or proteinuria) who may not in fact progress towards ESRD. The study describes how the use of the novel biomarker sTNFR1 from EKF can help target patients who are most likely to exhibit progressive Diabetic Nephropathy during a clinical trial and therefore will benefit most from new treatments.

biomarker of progressive Diabetic Nephropathy is evident. This large and exciting new data set confirms our own findings both here at EKF and with other collaborators. Having such impressive data presented at ASN puts us in front of the world’s leading kidney specialists and will pave the way to the adoption of sTNFR1 as a routine test in the management of Diabetic Nephropathy.”

There have been several other recent publications demonstrating that elevated circulating sTNFR1 levels are strongly associated with the subsequent development of advanced Diabetic Kidney Disease (DKD) in Type I and Type 2 diabetic patients.

For more information on EKF Diagnostics, please see www.ekfdiagnostics.com.

Consequently, this data further supports and validates use of EKF’s sTNFR1 test which is a microtitre plate, ELISA-based assay using monoclonal antibodies. The test accurately and reliably detects circulating levels of sTNFR1 in patient samples in just a few hours with minimal interference and crossreactivity. The test is easy-to use with standard laboratory equipment and can be performed with only 50 µL of blood serum or plasma.

Julian Baines, CEO of EKF Diagnostics commented: “Diabetic Nephropathy is the leading cause of ESRD worldwide and early identification of those most at risk of progression remains a significant unmet need. The growing awareness and utility of sTNFR1 as a

26 | January-February 2016 | Medical Device ASIA

About EKF Diagnostics www.ekfdiagnostics.com EKF Diagnostics Holdings plc, which includes the EKF Diagnostics, EKF Molecular, Stanbio Laboratory, DiaSpect and Selah Genomics brands, specializes in the development, production and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases.

Its new molecular division, EKF Molecular Diagnostics, focuses on technology used within the development of companion diagnostics, specifically within oncology. EKF products are sold in more than 100 countries around the globe, through a network of specialist distributors.

Point-of-care diagnostics: EKF Diagnostics designs and manufactures world-class diagnostic

devices, as well as distributing rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.

Central laboratory: EKF, through its wholly owned subsidiary, Stanbio Laboratory (Boerne, Texas, USA), manufactures a comprehensive range of clinical chemistry reagents.

In addition, EKF Life Sciences (Elkhart, Indiana, USA) manufactures enzymes used in reagent development and also provides contract fermentation facilities.

Molecular Diagnostics: In March 2013 EKF set up a new division to focus on molecular and companion diagnostics following the acquisition of UK-based 360 Genomics. EKF Molecular Diagnostics’ technology, PointMan™, is capable of detecting mutant genes from tiny biopsy and blood samples and has recently entered a partnership with the world renowned cancer research center at Massachusetts General Hospital, USA. EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.

Medical Device ASIA | January-February 2016 | 27

Safer, More Effective Drugs Will Push Vasculitis Treatment Market Value to $558 million by 2024

T

he vasculitis treatment market in the US and major European pharmaceutical markets (France, Germany, Italy, Spain, and the UK) is expected to expand in value over the next decade, from under $342 million in 2014 to over $558 million by 2024, at a Compound Annual Growth Rate (CAGR) of 5.1%, according to research and consulting firm GlobalData.“ “The company’s latest report* states that the leading driver of this reasonably robust growth will be the anticipated launches of five biologics for the treatment of various forms of vasculitis, including BristolMyers Squibb’s (BMS) Orencia, Johnson & Johnson’s Remicade, GlaxoSmithKline’s (GSK) Benlysta and Nucala, and Roche’s Actemra.“ “Alexandra Annis, MS, GlobalData’s Analyst covering Immunology, says: “The regulatory approval of these drugs throughout the forecast period will introduce four novel mechanisms of action (MOAs) to the market, which will address current unmet needs well.“ The greatest unmet needs in the vasculitis market are improved safety and efficacy for both induction and maintenance therapies, as induction regimens for the management of vasculitis typically come with a considerable list of side effects.

GlobalData believes the improved effectiveness and lack of inconvenient side effects that come with the introduction of these new MOAs offer exciting prospects for drug companies.

Annis explains: “The approval of biologics has the potential to result in big profits for pharma, as the cost of using them to treat a patient with vasculitis surpasses $16,000 per year. For this reason, vasculitis is an attractive area for label expansions.

The analyst adds that Roche’s

Actemra, BMS’s Orencia and GSK’s Nucala are anticipated to be the most successful of the new vasculitis treatment market entrants, as they have demonstrated strong efficacy and safety in clinical trials.

Despite this, there will be barriers preventing the vasculitis market from reaching its full growth potential during the forecast period.

Annis continues: “The high cost of biologics will limit their uptake, especially in cost-conscious markets that are facing austerity measures.

Cheaper biosimilars will challenge established brands.

In addition, there will be challenges in gaining reimbursement of biologics approved as induction therapies for use as maintenance therapies, such as Rituxan.

OpportunityAnalyzer: Vasculitis – Opportunity Analysis and Forecast to 2024 This report provides analysis of the vasculitis treatment space across the six major market of the US, France, Germany, Italy, Spain and the UK, including annualized data from 2014 through to 2024. It discusses market characterization, unmet needs, and implications for the vasculitis arena, including a strategic competitor assessment.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

For guidelines on how to cite GlobalData, please see: http:// www.globaldata.com/ QuotingGlobalData.aspx ABOUT GLOBALDATA-“GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better,

28 | January-February 2016 | Medical Device ASIA

more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information, please contact our Press Office on +44 (0)161 359 5822 or at pr@globaldata.com.

Gain access to our latest press releases and expert analysis on developments in your industry. Subscribe to our RSS feed for the Pharmaceuticals industry, follow our LinkedIn Pharma Showcase Page, or connect with us on: Facebook | LinkedIn | Twitter

Customized Sensor and Connectivity Solutions Key to Helping Transform Patient Care, Say TE Connectivity Experts versatile technology enables true non-contact measurements on the forehead (i.e., temporal artery.) The same principle can be used to monitor skin temperature in therapy.

These sensors also can be used for non-contact temperature measurement (blood or infusion packs) as well as for advanced temperature control in dialysis application.

T

E to showcase broad product portfolio at COMPAMED, the leading global trade event for medical technology suppliers TE experts also to participate in Suppliers Forum by DeviceMed to discuss latest developments in thermopile temperature sensors and customer-driven electronics leading to miniaturization of medical devices TE Connectivity (TE), a world leader in connectivity, showcased its broad range of products and capabilities at COMPAMED, the leading trade event for suppliers of medical technology. The event took placeed in November 16-19 in conjunction with MEDICA, one of the world’s largest medical trade fairs. TE’s exhibit was located in Hall 8b, Booth E20.

TE showcased a broad range of products, including sensors, fine wire cable assemblies, catheters and guide wires, laser processing,

extrusions and tubing, medical balloons, and testing capabilities.

Experts will be onsite to discuss and demonstrate the company’s latest innovations for interventional, surgical, imaging, patient monitoring and diagnostic applications.

“We have a strong history of driving innovation to advance the medical device industry,” said Brian Cunkelman, vice president and general manager, TE Medical. “This unique forum is ideal as our engineers work closely with device manufacturers to provide custom solutions and transform patient care.”

“Electronic systems in medical equipment, devices and probes rely on sensor signals as a basis for control activities, accurate diagnosis and treatment,” added Armin Wellhoefer, TE’s global leader for medical sensors. “We offer a wide range of sensor types, including temperature, piezo film, force and pressure. Our sensors are used for

the diagnosis or treatment of many pathologies including heart disease and diabetes.”

TE Sensor Solutions designs and manufactures sensors to exacting specifications, with ISO 13485 certification and FDA registration for various products. TE engineers provide full support of applicationspecific, standard and custom requirements, from product concept through manufacturing.

TE experts also will participate in the Suppliers Forum by DeviceMed (Hall 8b, Stand G40), where engineers and technology specialists representing leading industry companies and organizations will discuss current developments along the process chain. TE experts and topics to be discussed include:

Vitaliy Epshteyn, CTO and senior director, Global Engineering and Portfolio Management, TE Medical, discussed recent trends in customer-driven electronics and profile products for ultrasound, surgical and interventional applications. Many of these innovations enable device miniaturization, which is vital to the future of patient care, enabling procedures to become less-invasive, allowing patients to heal more quickly. Miniaturization positions OEMs to compete in today’s medical device industry.

For more information on TE’s connectivity and sensor solutions for the medical industry and presence at the event, visit http:// www.te.com/compamed

Dr.-Ing. Dirk Nüsse, engineering manager for temperature sensors, presented a thermopile sensor that provides a stable output signal even if the optical distance varies. This Medical Device ASIA | January-February 2016 | 29

ELECTROCORE APPOINTS DESITIN TO LAUNCH GAMMACORE FOR THE TREATMENT OF PRIMARY HEADACHE ACROSS GERMANY

E

lectroCore’s non-invasive vagus nerve stimulation device, gammaCore, will be launched across Germany by Desitin for the treatment of migraine and cluster headache. The agreement with Desitin who are specialists in the CNS area took effect on January 1st, 2016.“ “Desitin, who are a pan European pharma based in Hamburg, presently focus on treatments in Parkinson’s and epilepsy. Their existing CNS salesforces covering these diseases will also detail gammaCore to those specialist neurologists who also treat headache.“ “GammaCore is well known in Germany as many of the headache centres across the country took part in the successful clinical trial program.“ “CEO of electroCore JP Errico

commented, “We are very pleased to partner with Desitin. Their understanding of the CNS marketplace in Germany will bring great benefits to patients. It was very important to us to have a pharmaceutical partner as they better understand the business model which is most appropriate for bioelectronics.”“ “CEO of Desitin commented, “We believe that with our expertise in the CNS area and with a specialist salesforce we will be able to explain the significant therapeutic benefits of gammaCore firstly to the neurologists and through them to the patients.

Compared to most treatments in this area gammaCore has virtually no side effects and has proven to be very effective in both preventing and treating cluster headache and migraine. We are really delighted to be working with electroCore to

30 | January-February 2016 | Medical Device ASIA

bring this treatment to patients across Germany.”

“About electroCore“electroCore LLC, the New Jersey based bioelectric pharma company, is focused on developing noninvasive vagus nerve stimulation therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology, and respiratory fields. The company’s initial target is the treatment of primary headaches (migraine and cluster headache), and the associated chronic co-morbidities of gastric motility, psychiatric, sleep, and pain disorders that drive disproportionately large direct and indirect costs within the healthcare system and society. “www.electrocoremedical.com“ “Desitin background““DESITIN ARZNEIMITTEL GMBH which was

founded in 1919 and is based in Hamburg is a medium sized pharma focused on the development and sales of medication for illnesses of the central nervous system (CNS) particularly the treatment of epilepsy, Morbus Parkinson, dystonia and now primary headache.““The company activities are focused on Europe with subsidiaries in 11 countries and distributors in 12 others.

UZBEK NATIONAL WALKS FOR THE FIRST TIME AFTER 9 YEARS, THANKS TO THE EXPERTS AT MEDANTA BONE AND JOINT INSTITUTE GURGAON to normal.

About Medanta Bone and Joint Institute:“Medanta Bone and Joint Institute is a super-specialty Institute which aims to provide world-class, evidence-based treatment for various orthopaedic disorders and sports injuries. A team of highly skilled and dedicated orthopaedic surgeons who have trained extensively in their respective fields are led by Dr. Ashok Rajgopal, an internationally acclaimed knee and joint replacement surgeon.

I

n yet another breakthrough surgery at the Medanta Bone and Joint Institute (MBJI), the doctors restored the mobility impairment of an Uzbek national. The patient, Ms. Guzal Ruzamatova was suffering from the condition since the last 9 years. The 55 year old lady had met with a traffic accident in 2006 and sustained a fracture of the shaft of her left femur (the long thigh bone).

While she was treated locally and underwent a series of surgeries for fracture fixation, implant failure, infection from 2006 to 2009, the issue could not be corrected. Finally in 2009 all the implants and external fixators were removed and the leg was left to heal on its own.

As a result of all these procedures, the patient was practically wheelchair bound with barely any mobility.““After years of living with pain, the patient was finally recommended to Medanta Bone and Joint Institute in India where a team of doctors lead by Dr. Ashok Rajgopal, Chairman Medanta Bone and Joint Institute (MBJI) recognized that the patient had a shortening of about 12.5 cms of the left leg. She had an extremely limited range of movement of just 20-60 degrees of

the left knee.

Additionally, the shoe raise worn by her was extremely heavy and did not allow for much motion.““Dr. Rajgopal and the team at Medanta Bone and Joint institute immediately recommended her for a segmental resection and a total knee replacement surgery, both cutting edge procedures that are championed by Dr. Ashok Rajgopal and his team. In a surgery that lasted almost six hours, both the procedures were successfully performed by the team on December 17th 2015.“ “Speaking about the surgery Dr. Ashok Rajgopal, Chairman - Medanta Bone and Joint Institute said “When we first met her, she was severely disabled and was a wheelchair bound patient. She had had 9 previous surgeries and multiple scars on the same leg. Her limb was a little over 12cm short and had an ununited fracture of the thigh bone.

We did a segmental resection implant and restored about 11cm of her leg length without damaging any nerve or blood vessel, thereby restoring her quality of life.

surgery, Ms. Guzal is a happy lady and is re-discovering the joys of an independent life free from the handicaps. She is comfortably mobile albeit with a walker and independent in all her personal activities of daily living and can bend her knee normally.

She has regained 11cms of length in her left leg basically making the length of both her legs almost the same further aiding her movement.

With a small insole of 1.5cms she can further do away with any need of wearing the cumbersome shoe raise in future. Narrating about her experience, Ms. Guzal said “I was treated at Tashkent earlier but it didn’t help me much. I didn’t have any hope of getting back my leg and walking normally. I am grateful to everyone at Medanta for the treatment and returning my life back

Committed to evolving knee surgery procedures and techniques, Dr. Rajgopal is the first Orthopaedic Surgeon in India to perform virtual total knee replacement surgery which has made him a member of designer team of surgeons responsible for the development of latest knee implant - Persona Knee System.

Also, he has successfully developed instruments for MIS total Knee replacement surgery. Medanta Bone and Joint Institute is equipped with advanced cutting edge technology, like: Computer Navigation System with High Definition Cameras· Arthroscopic Equipment for performing technically challenging procedures. State-of-the-Art "Bone Bank. Alpha Operation Theatre which can be accessed from anywhere in the world via satellite linkage. A modern rehabilitation department with gait analysis lab, hydrotherapy pool, electrotherapy equipment and state of art gym for rehabilitation.

Today, almost three weeks after Medical Device ASIA | January-February 2016 | 31

Medica 2015 Dusseldorf: TAIWAN SHOWCASES ITS LATEST INNOVATIVE PRODUCTS AND TECHNOLOGIES increased more than 340 percent.“ Mr. Ke’s special remarks was followed by Dr. Yio-Wha Shau, Vice President and General Director of the Biomedical Technology and Research Laboratories at the Industrial Technology Research Institute (ITRI). He introduced the healthcare and biotech branches as two of the ten emerging industries to drive the next wave of economic growth in Taiwan.

He also focused on Taiwan’s Innovative Medical Device Ecosystem, including the Supra Incubation and Integration Center (SI2C), a service platform designed to integrate Taiwan into the medical global ecosystem and grow it into a powerhouse for developing and commercializing medical devices.

Taiwan’s top medical device companies presented their best products at a press conference at Medica 2015.

A

t Medica 2015, the world’s largest medical market place, numerous national and international journalists and industry professionals took the chance to inform themselves about the cutting-edge product highlights of Taiwan’s medical device companies.

At the “Taiwan Excellence New Products Launch”, that took place today, November 17th, the latest

winners of the Taiwan Excellence Award were at the forefront: Advantech Co., Ltd., BenQ Materials Corp., HIWIN Technologies Corp. and Leadtek Research Inc. The award is presented annually by the Bureau of Foreign Trade, Taiwan’s Ministry of Economic Affairs.

The company representatives from Advantech, BenQ, HIWIN and Leadtek demonstrated impressively why Taiwanese medical devices are recognized as innovative and userfriendly. This is especially due to the vibrant medical research environment and a strong protection of intellectual property in Taiwan.

32 | January-February 2016 | Medical Device ASIA

Furthermore, Taiwan’s strength in ICT and automation provide the foundation for advancing medical technology and to deliver affordable healthcare.

Mr. Wen-Cheng Ke, the Director of the Economic Division, Taipei Representative Frankfurt Office in the Federal Republic of Germany, opened the press conference by stating that “Germany is Taiwan’s biggest trading partner in Europe.

Two-way trade reached US $15.5 billion in 2014, accounting for 24% of Taiwan’s total trade with the continent. Last year, investments from Germany in Taiwan has

Following his speech, the speakers of the four Taiwan Excellence awardwinning brands were center stage with their product presentations.

Mr. Michael Kishore Bhagwandien, the Medical Sector Sales Director in Europe at Advantech Co. Ltd., spoke about “Care at the Bedside” and presented a 7’’ clinical-grade Windows-based tablet. The Pocket Pad is a revolutionary, handheld mobile computing platform designed especially for clinical applications.

Since it works with Windows 8, the data transition from desktop to mobile is smooth. It holds a variety of benefits for medical staff, enhancing work efficiency and

improving data accuracy. The tablet can be easily cleaned, it is water and dust-proof and has been droptested from a height of 90 cm.

BenQ Materials Corp. was represented by Mr. Waye Chen, Sales Manager. In his presentation “Hemostatics and Wound Management”, he introduced two products of the AnsCare Series.

The hemostatic series works with chitosan – a biocompatible polysaccharide – which has an excellent effect on bleeding control and functions as a barrier protecting against bacteria. The AnsCare ChitoGauze increases the survival rate of patients who experience massive blood loss, including wounded soldiers. The AnsCare ChitoGauze is made of 100% wetspun and needle-punched chitosan and has superior hemostatic and blood loss-reducing effects that have been proven in clinical studies.

The AnsCare ChitoClot Artery Compression Device is designed for hemostatis after surgery. While developing this tool, BenQ Materials Corp. focused on designing an easy-to-use device, which helps bleeding control for patients.

Cyrus Tong, the General manager of HIWIN, presented the Robotic Gait Training System, an innovative treatment solution for locomotion and neuro-rehabilitation training. The system provides a solution for gait rehabilitation therapy to patients with varying degrees of impairment. The Robotic Gait Training System not only benefits the patients while exercising but assists the therapist by decreasing physical exertion and uncomfortable body positions during patient setup.

The system is safe, simple and costeffective. Compared to the therapist-centered rehabilitation, the

robotic therapy provides a better treatment by motivating the patient through their interaction with the device. The Robotic Gait Training System is space saving (approx.

1.95 m2), provides multiple gait

patterns and an intuitive user interface. The system’s high level of safety is thanks to its spastiscity detection and an emergency stop features. The fourth highlight of the day was the Amor H1 Heart Rate

and Activity Monitor, which was presented by Mr. Kevin Tay, a Sales Manager of Leadtek Research Inc. This latest product trend is designed for a variety of target groups: the elderly, walkers, runners and

Medical Device ASIA | January-February 2016 | 33

bicyclists.

This compact and lightweiht wearable device is capable of measuring the heart rate and analyzes the autonomic nervous system. Thanks to this device, users can exercise safely and more effectively. Records can be tracked anytime and anywhere in Amor’s mobile health cloud. An additional benefit analyzes sleep quality, informing users of their deep and light sleep durations, wake times, total sleep time and sleep quality score.

All Taiwan Excellence award-winning brands at this event are representative of Taiwan’s competitive edge in the health and pharmaceutical sector. Taiwan has long played a vital role in the global supply of consumer electronics and has gained an impressive foundation of knowledge in numerous ICT sectors.

It is now utlizing its ICT and automation expertise to further expand its presence in the global medical device market. This expansion has helped attract foreign firms looking to establish partnerships with Taiwanese manufacturers.

Information about Taiwan Excellence / Bureau of Foreign Trade and TAITRA: The symbol of Taiwan Excellence was established in 1992 by Bureau of Foreign Trade, Taiwan’s Ministry of Economic Affairs, and subsequently the Taiwan Excellence Selection was launched the following year. The selection is based on the distinct criteria of R&D, quality, design and marketing.

Taiwan Excellence awarded products using cutting-edge innovation and meeting the highest quality will represent Taiwan on the international stage to reinforce the

buyer’s confidence and continue building a favorable impression for Taiwanese products. This year marks the 22nd selection, making the symbol of Taiwan Excellence a prestigious brand for enterprises in Taiwan to strive to be recognized by and is highly reputed throughout the world. Please visit www.taiwanexcellence.org for more information.

Organized by: The Bureau of Foreign Trade (BOFT), under The Ministry of Economic Affairs of Taiwan, is responsible for implementing policies and regulations governing foreign trade, economic cooperation, and foreign investments. Established in January 1969, the BOFT's role and position have undergone continual adjustments to meet the needs of the shifting international economic and trade environment. The BOFT has been guiding and working with the Taiwan External Trade Development Council (TAITRA) in numerous trade promotion projects and activities both internationally and domestically. Having worked closely with

34 | January-February 2016 | Medical Device ASIA

TAITRA for many decades, the BOFT continues to entrust TAITRA with various critical government projects relating to trade and investments, promoting Taiwan on every international aspect.

Implemented by: Founded in 1970 to help promote foreign trade, the Taiwan External Trade Development Council (TAITRA) is the foremost non-profit, semigovernmental trade promotion organization in Taiwan. Jointly sponsored by the government, industry associations, and several commercial organizations, TAITRA assists Taiwanese businesses with reinforcing their international competitiveness and in coping with the challenges they face in foreign markets. TAITRA boasts a wellcoordinated trade promotion and information network consisting of over 1,200 trained specialists stationed throughout its Taipei headquarters and their 60 branches worldwide. Together with its sister organizations, the Taiwan Trade Center (TTC) and Taipei World Trade Center (TWTC), TAITRA has created a

wealth of trade opportunities through effective promotion strategies.

PR Contact: TAITRA: Sharon Su Phone: +886.2.2725.5200 Ext. 1392 E-Mail: sharon@taitra.org.tw Yamaoka International Public Relations GmbH: Birthe Ahting Phone: +49 (40) 300326-28 E-Mail: ahting@yamaoka.de

ALCHEM INTERNATIONAL LAUNCHES THIRD GENERATION PHYTOMEDICINE TO COMBAT COUGH, COLD AND FLU

I

n international clinical trials, PhytoRelief-CC’s patented formulation has proven to be very effective for conditions like cold and flu symptoms, upper respiratory tract infections, and mucosal lesions of the mouth and throat Alchem International launches the third generation phytomedicine called PhytoRelief-CC to combat symptoms of cough, cold and flu.

PhytoRelief-CC comes in the form of chewable sugar-free lozenges which contain concentrated and purified molecular extracts of turmeric (haridra), ginger (zingiber officinale), and pomegranate (dantabija). The synergistic effect of these nature-derived ingredients offers a host of benefits to quickly and naturally cure symptoms of cough, cold and flu.

PhytoRelief-CC has very potent antiviral, anti-bacterial, immunemodulatory, anti-inflammatory, antiallergic and anti-oxidant properties.

It has been developed using AlchemLife’s proprietary Phytoplex™ technology based on cutting-edge science to deliver unsurpassed efficacy without any side effects.

Phytoplex™ technology is Alchem’s proprietary extraction process which isolates active plant molecules in a way that preserves the `natural balance’ and ‘synergistic effects’ present in the original plant material.

We expect a very encouraging response as there is presently no natural offering in the market that is backed by clinically proven results for the prevention and treatment of symptoms of cold, cough and flu.”

be distributed in phases across the country at all retail and pharmacy outlets.

Sudhir Mehra, Senior Vice President, Alchem International, said, “The product will first be made available across North India and subsequently register its presence in other parts of India.”

About Alchem International

In European clinical studies published in prestigious peerreviewed international journals like Minerva Gastroenterol Dietol and Minerva Medica, PhytoRelief-CC has proven to be very effective for conditions like cold and flu symptoms, upper respiratory tract infections, and mucosal lesions of the mouth and throat (associated with Bechet’s disease).

Compared to the placebo, PhytoRelief-CC led to reduction of signs and symptoms of cold and flu within 2weeks, 83 % reduction in bacterial load within 3 days, and effective anti-viral activity against various strains of influenza. Tests have also shown significant improvements in treating disorders of the mouth, throat and upper respiratory tract infections within just 4-5 days. Priced at Rs199 for a strip of 10 lozenges, PhytoRelief-CC will

Alchem International develops and markets Third Generation Phytomedicines – i.e. phytomedicines which undergo international clinical trials for efficacy and safety - under the master brand AlchemLife. Third Generation Phytomedicines are more efficacious than regular phytomedicines and have no side effects because of Alchem International’s proprietary extraction Phytoplex™ Technology.

Third Generation Phytomedicines have been developed by applying modern science to traditional systems of medicine from across the world including Chinese, African, South American, European and Indian. Third Generation Phytomedicines are ideally suited for long term treatment of ailments as they have no side effects. They can be used for primary therapy, or as adjuncts to primary therapy, that deliver long-term results with no side effects.

Alchem International has over 75 years of experience in manufacturing phytochemical-based Active Pharmaceutical Ingredients (APIs). Its phytochemicals plant, the biggest in India, is certified by the US FDA, WHOGMP and AFSSAPS (The French Agency for the Safety of Health Products) and vendor validated by companies across the world. 80% of its revenues are generated from global exports.

The top selling Third Generation Phytomedicine brands under AlchemLife include Liverubin (Liver care), Flexiqule (Joint care), Miraqule C 100 ( Cardio care), ProstaQuil (Prostate care) and PhytoRelief CC (Flu care).

Raman Mehta, Founder, Alchem International, said, “PhytoRelief-CC provides quick and effective relief naturally, combining the power of traditional medicinal herbs with cutting-edge science and research.

Medical Device ASIA | January-February 2016 | 35

EASY-ACCESS WEBINAR E-COURSE FROM PTI HELPS PHARMACEUTICAL MANUFACTURERS IMPLEMENT SUCCESSFUL QUALITY BY DESIGN STRATEGIES

P

harmaceutical Training International (PTI), the leading supplier of online and public event-based training courses for the pharma, biotech and medical device sectors, continues its easy-access series of webinar e-courses with guidance on implementing an effective Quality by Design (QbD) approach. Professionals working both directly and indirectly in pharmaceutical manufacturing will benefit from industry expert, Emil W. Ciurczak’s, decades of experience in the pharmaceutical industry and expertise in analytical method development and improvement.

Entitled ‘The QbD outlook in pharmaceutical manufacturing’ the ecourse will take place at 2:30 PM (UK) on Wednesday 9th December, and show participants how an effective QbD strategy can minimise costs and maximise efficiencies in manufacturing processes.

As the pharmaceutical market becomes ever more competitive, manufacturers need to ensure their processes are as time- and costeffective as possible. This requires a thorough understanding of the chemical and mechanical properties

of the elements used to make a pharmaceutical product, as well as the manufacturing processes involved. In this webinar e-course, Emil Ciurczak will provide a complete overview of implementing QbD, including the economic reasons, regulatory requirements, technologies, concepts for software and compliance, and best practices to successfully roll out QbD with minimal risk.

He will also address specific queries in an interactive question and answer session at the end of the webinar. Participants will be able to use the knowledge gained from this course to develop a QbD strategy for their own manufacturing processes, improving quality, reducing variance and time to market, as well as HVAC and materials costs.

PTI’s Managing Director, Rosie Bernard, comments: “In today’s market, pharmaceutical manufacturers really need an edge to stay competitive and maximise their return on investment. At PTI, we understand that the correct implementation of a Quality by Design strategy can make a real

36 | January-February 2016 | Medical Device ASIA

difference. In this latest session of our series of webinar e-courses, we provide easy access to Emil’s considerable experience in pharma.

Having worked in the industry since the 1970s, he will ensure all who participate in the session leave with a thorough understanding of QbD and the considerations needed to make it successful.”

Learn more and register for this webinar e-course.

For more information, please visit http://www.pti-global.co.uk/. Follow PTI on twitter @PTI_Courses for realtime updates and insights.

About PTI PTI is a global interactive training

partner committed to the personal progression of aspiring life science professionals. PTI provides multidiscipline and company-wide training solutions to the global pharmaceutical community. Based in London, UK, PTI has an expanding assortment of courses specifically tailored to the (bio)pharma and medical device industries which range in method from distance learning to tailored on-site training and include interactive game-based learning modules. For more information, visit http://www.ptiglobal.co.uk/.

Pharmaceutical Training International +44 (0)20 7017 7000 registration@pti-global.co.uk http://www.pti-global.co.uk/

Make it to Market – PTI Explains Strength and BCS-based Biowaivers Learn more, and register for these webinar e-courses For more information, please visit http://www.pti-global.co.uk/. Follow PTI on twitter @PTI_Courses for realtime updates and insights.

Live, easy-access webinar e-courses from PTI equip (bio)pharma companies with the knowledge to make successful biowaiver applications Pharmaceutical Training International (PTI), the leading supplier of online and public event-based training courses for the pharma, biotech and medical device sectors, is launching a series of easy-access and cost– effective webinar e-courses to guide pharma professionals through the industry challenges they face.

The first two webinars will provide advice on making applications for biowaivers in the EU and US, each including live question and answer sessions. By equipping themselves with this knowledge, participants will be able to push products to market faster and with less hassle and expense.

Careful consideration is required in

bringing a generic pharmaceutical entity to market, including the strategic use of biowaivers to bypass the need for expensive and time-consuming clinical studies.

Industry expert Jean-Michel Cardot, Professor of the Department of Biopharmaceutics and Pharmaceutical Technology, Universite d’Auvergne, will guide participants through two webinars on this subject, the first on Strength Biowaivers, at 2:30 PM on Monday 30th November, and the second on BCS-based Biowaivers at 2:30 PM on Monday 7th December.

These two webinar e-courses will provide both new and experienced personnel with a thorough grounding in biowaivers, including the types of biowaiver available, requirements in the EU and US, the application process, and common pitfalls encountered. In each, Professor Cardot will examine the

optimal strategy to implement a biowaiver, and hold a comprehensive question and answer session to address specific queries. Participants will gain the confidence and skills to implement a strategic approach to biowaiver applications for fast tracking their products through their organisations’ pipeline.

“Every member of our team aims to provide the very best training to (bio)pharmaceutical professionals,” comments PTI’s Managing Director, Rosie Bernard. “This new series of webinar e-courses will focus on ‘hot topics’ that need to be addressed by the industry to ensure new drugs are successfully brought to market. Our biowaiver webinars are designed for both new and experienced personnel alike, and will provide participants with the expertise to make successful biowaiver applications, helping them accelerate their drugs’ route to market.”

About PTI PTI is a global interactive training partner committed to the personal progression of aspiring life science professionals. PTI provides multidiscipline and company-wide training solutions to the global pharmaceutical community. Based in London, UK, PTI has an expanding assortment of courses specifically tailored to the (bio)pharma and medical device industries which range in method from distance learning to tailored on-site training and include interactive game-based learning modules. For more information, visit http://www.ptiglobal.co.uk/.

Pharmaceutical Training International +44 (0)20 7017 7000 registration@pti-global.co.uk http://www.pti-global.co.uk/ Jean-Michel Cardot

Medical Device ASIA | January-February 2016 | 37

MEDICAL FAIR ASIA 2016

THE HALLMARK EVENT FOR ASIA’S MEDICAL AND HEALTHCARE SECTOR 11th International Exhibition on Hospital, Diagnostic, Pharmaceutical, Medical & rehabilitation Equipment & Supplies, 31 Aug – 2 Sep 2016, Marina Bay Sands, Singapore | www.medicafair-asia.com

MEDICAL DEVICE ASIA (MDA) sits down with Mr Gernot Ringling, (GR) Managing Director of Messe Düsseldorf Asia Pte Ltd to talk about Southeast Asia’s most definitive event - MEDICAL FAIR ASIA 2016.

our plans for the future.

MDA: This year's MEDICAL FAIR ASIA is being held at a new venue, what went into that decision?

GR: MEDICAL FAIR ASIA has been growing immensely since the first staging in 1997 and continues to expand well into its 11th edition.

Our biggest challenge right now is locating a large enough space to strategically develop our future editions, especially more so with the co-location of our other concurrent event, MEDICAL MANUFACTURING ASIA. This change in venue presents an opportunity for us to put in place

We will be moving to the new venue, the Sands Expo & Convention Centre, Marina Bay Sands Singapore, for the 2016 edition, scheduled to be held from 31 August to 2 September. The event will present an exhibition space of 15,000sqm, which is a 40% increase from the previous installment in 2014.

MDA: The show seems to be undergoing significant growth in popularity. To what do you attribute that? How many exhibitors and attendees do you expect?

GR: I would say that the first and most important factor has been our ability to adapt and adjust to the dynamic Southeast Asia healthcare

38 | January-February 2016 | Medical Device ASIA

landscape, characterized by the diverse nature of the region’s healthcare systems which are at varying stages of evolution, and offer both our exhibitors and visitors the best possible response to their needs. We work closely with our exhibitors. We know their products, solutions, strategies and target audience. We also comprehend the visitors’ needs and their expectations. With this understanding, we are able to link up exhibitors with relevant distributors, suppliers and agents and vice versa; and cater to the different solutions and visitor needs across the various specializations and broad healthcare channels. This is a key element contributing to the show’s growth in popularity as the strategic business and procurement platform for the industry in this region.

Strategically positioned as a ‘central’ exhibition for Southeast Asia, connecting all countries in ASEAN with a total population of 600 million1, the show in 2014 attracted a notable 10,504 trade visitors of which 85% came from ASEAN countries.

The Southeast Asia medical and healthcare industry is also riding on a strong growth momentum. The increasing awareness of quality healthcare, rapidly ageing populations, higher life expectancy, rising trend in medical tourism and booming economic development are among the factors contributing to this growth. Governments in this part of the world are also driving initiatives to create a more robust healthcare sector to meet their citizens’ escalating needs, further

fueling the region’s industry growth.

The show rides on this growth and provides the fitting platform for industry players to tap the unprecedented business opportunities in this region.

MEDICAL FAIR ASIA 2016 is expected to attract 1,000 exhibitors from 45 countries and 15,000 quality trade buyers and decision makers.

MDA: Did anything surprise you about last year's event?

GR: The 2014 edition posted better-than-expected growth, with a 50% increase in the number of exhibiting companies compared to the previous edition in 2012 and a record-setting 15 national and group pavilions from Austria, Canada, China, France, Germany, Hungary, Italy, Japan, Korea, Malaysia, Singapore, Taiwan, Thailand, UK and USA. The show also recorded a 20% increase in visitor attendance from the previous edition, which included a strong line-up of government level delegations and hospital management personnel from Hong Kong, India, Malaysia, Philippines, Turkey and Vietnam.

We are surprised that amidst the declining business dynamism and economy slowdown in 2014, the show’s exhibit-space-growth and attendance-growth have managed to outpace each other. We are expecting this positive growth to continue in 2016.

MDA: Who should exhibit at this show?

GR: Companies looking to tap the burgeoning growth in the Southeast Asia healthcare market should definitely exhibit at MEDICAL FAIR ASIA, as there is a growing number of potential buyers in this region.

The show is also the ideal platform to launch the latest medical technology and innovations, and showcases a wide range of exhibitors in the areas of hospital, diagnostics, pharmaceutical, medical and rehabilitation equipment and supplies for this region.

For the 2016 edition, we are expecting 20 national pavilions and country groups, including a U.S. pavilion as well as a U.S. group participation led by Enterprise Florida.

Companies in the medical technology sector can also take part in the co-located Medical Manufacturing Asia exhibition, which will feature an extensive range of products covering the upstream and downstream processes in the medtech sectors.

MDA: What will be some of the themes and highlights at this year's exhibition?

GR: The event, taking the theme “where healthcare connects with technology”, aims to bring the latest medical technology and industry happenings to the region.

The special highlights for the 2016 edition include Digital Healthcare and Sports Rehabilitative Care platforms, and an inaugural MEDICINE + SPORTS CONFERENCE ASIA featuring new sports medical therapies, and innovative products for prevention, recovery and population health management.

MDA: What advice would you have for first time exhibitors to make the most of their time at the show?

GR: My advice would be for first time exhibitors to actively market and promote themselves to seize the

interest of attendees prior to the event. At MEDICAL FAIR ASIA, we offer a suite of complimentary publicity opportunities to help exhibitors publicize their participation. Our marketing communications team regularly shares news and information about the event with the international trade media. I would definitely encourage first-time exhibitors to share their latest news with us so that the information may be featured in the event’s press releases emailers and other publicity platforms. Nearing to the event, exhibitors’ product offerings will also be featured in the Show Updates which will be printed and mailed out to 30,000 distributors and medical professionals in Asia.

Apart from that, once a company confirms its participation, a write-up together with a photo of the intended exhibit will also be uploaded onto the show website and be included in the show catalogue which will be distributed onsite.

I would also advise first-time exhibitors to deepen their understanding of the attendee demographics and specific product interests in order to target them more effectively. I would recommend exhibitors, especially first time participants, to proactively use our complimentary Business Matching platform to receive recommendations on who they should meet as well as to schedule meetings before and during the event.

yourself first and act as a stepping stone onto other markets, making it an ideal location to understand market trends and responses across the various countries in the region.

The city-state is a multi-racial melting pot where English is most commonly used amongst the four official languages together with Mandarin, Tamil and Malay.

Singapore is also a fun and entertaining place to be, and certainly one of the world’s most vibrant and exotic cities to visit. Not only is it home to beautiful architecture, it also boasts of a divergent cultural heritage, knockout cuisine, a burgeoning bar scene and a heartstopping skyline at night. My top picks would definitely include the Botanical Gardens which has recently become a Unesco World Heritage site, the ’Singapore Flyer’ for the breath-taking sights of Singapore and of course the buzzing Clarke Quay and Boat Quay to sip drinks and indulge in some of Singapore’s best culinary treats by the Singapore River.

MDA: Is there anything else that people should know that we’ve missed?

MDA: What should exhibitors know about Singapore, its customs, special attractions -- and what languages spoken there?

GR: MEDICAL FAIR ASIA is held concurrently with the 3rd MEDICAL MANUFACTURING ASIA, an exhibition and conference focused on manufacturing processes for medical technology. Both trade fairs are organized by Messe Düsseldorf Asia and are modelled after the world’s largest and leading medical trade fairs, MEDICA and COMPAMED, organized by Messe Düsseldorf in Germany.

GR: Singapore is definitely one of the easiest places to do business in Asia, especially in the Southeast Asia region. It is a great place to establish

For more information please visit, www.medicalfair-asia.com or contact medicalfairasia@mda.com.sg

Medical Device ASIA | January-February 2016 | 39

Haydon Kerk Motion Solutions Introduces Miniature Stepper Motor Linear Actuator

H

aydon Kerk Motion Solutions has expanded its 15000 Series linear actuators with the addition of the smallest linear actuator in Haydon Kerk’s extensive stepper motor line. The new linear actuators occupy a minimal 0.6” (15mm) diameter space and incorporate some of the mostadvanced motion control technology available today. Included in that very small package are numerous patented innovations that provide customers high performance and durability.

15000 Series linear actuators are available in two designs - captive and external linear versions –and in a wide variety of resolutions, ranging from 0.02mm to 0.10mm per step.

The actuators deliver thrust of up to 60 oz (1.7 kg) without compromising long life or cost. Models also can be micro stepped for even finer resolution. A proprietary manufacturing process that incorporates

engineering thermoplastics in the drive nut and a rolled stainless steel lead screw allows the motor to be highly efficient and durable.

Typical applications include medical equipment, semiconductor handling, valve control, X-Y tables, handheld instruments, and many more. In addition to standard configurations, Haydon Kerk Motion Solutions can custom design the actuators to meet specific application requirements.

For more information about Haydon Kerk Motion Solutions products, contact: Haydon Kerk Motion Solutions 1500 Meriden Road Waterbury, CT 06705 Toll free: 800243-2715;CT and International: 203756-7441. Website: www.haydonkerk.com About Haydon Kerk Motion Solutions, Inc. Haydon Kerk Motion Solutions is a business unit of AMETEK, Inc., a

40 | January-February 2016 | Medical Device ASIA

leading global manufacturer of electronic instruments and electromechanical devices with annual sales of $4.0 billion.

Haydon Kerk Motion Solutions is the joining of two world-class brands in the field of linear motion: Haydon Switch and Instrument, Inc. and Kerk Motion Products, Inc. Together as Haydon Kerk Motion Solutions, these brands offer a wide range of high-performance and high-precision linear motion products. Recognized as a leading manufacturer of stepper motorbased linear actuators, rotary motors, lead screw assemblies, and linear rail and guide systems used in niche market applications, Haydon Kerk Motion Solutions has developed industry-renowned brands built upon its technical innovation, versatility, customization, product durability, and dedicated customer service.

HAYDON KERK MOTION SOLUTIONS INTRODUCES MICRO SERIES ANTI-BACKLASH NUT FOR 2MM DIAMETER SCREWS

H

aydon Kerk Motion Solu tions, a recognized leader in linear and rotary motion solutions, has added the world’s smallest anti-backlash lead screw assembly design to its line of Micro Series screws (2mm diameter screws). Its ZBM nut technology can be customized to specific applications that require unique geometry and custom materials, such as Kerkite® composite polymers. Haydon Kerk also has inhouse molding and mold-making departments to help develop custom solutions for its customers.

This new Micro Series anti-backlash nut with optional TFE-coated screw is now available 24/7 at the Haydon Kerk Express Store.

Haydon Kerk has over 35 years of experience in the design of antibacklash technologies and precision lead screws. Its new Micro Series

ZBM nuts utilize a special nut thread system that, when combined with a radial force, provides simple backlash compensation. Initially designed for the optics-focusing market, the ZBM nut performs well in applications in which precise, smooth motion is required and space is at a premium.

The new nut falls within the current dimensional envelope of standard freewheeling nuts, making a transition to an anti-backlash system easier. The design also is optimized for high-quantity production, allowing for best-practice, highproduction efficiencies along with rock-solid performance.

Utilizing Kerkite® engineered polymers or customer-specified materials (including PEEK), Haydon Kerk can design and manufacture a lead screw nut that delivers smooth, efficient rotary-to-linear motion

conversion. In addition, with the use of a Kerkote® TFE coating, Haydon Kerk can effectively reduce the amount of torque required to produce the same amount of force. That, in turn, can lead to a longer assembly life as well as a possible reduction in motor size.

For more information about Haydon Kerk products, contact: Haydon Kerk Motion Solutions, 1500 Meriden Road, Waterbury, CT 06705. Telephone: (toll free) 800-243-2715 and (International) +1- 203-756-7441. Fax: 203-7568724. E-mail: info.haydonkerk@ametek.com. Web site: www.haydonkerk.com.

About Haydon Kerk Motion Solutions, Inc. Haydon Kerk Motion Solutions is a business unit of AMETEK, Inc., a leading global manufacturer of electronic instruments and electromechanical devices with annual sales of $4.0 billion. Haydon Kerk Motion Solutions is the joining of two world-class brands in the field of linear motion: Haydon Switch and Instrument, Inc. and Kerk Motion Products, Inc. Together as Haydon Kerk Motion Solutions, these brands offer a wide range of high-performance and high-precision linear motion products. Recognized as a leading manufacturer of stepper motor-based linear actuators, rotary motors, lead screw assemblies, and linear rail and guide systems used in niche market applications, Haydon Kerk Motion Solutions has developed industry-renowned brands built upon its technical innovation, versatility, customization, product durability, and dedicated customer service.

Medical Device ASIA | January-February 2016 | 41

Obesity can lead to sever life threatening complications

W

atch that bulges, exercise and eat right; take a pledge on thE anti-obesity

day

Being overweight or obese isn't just a cosmetic problem anymore. Being obese can compromise your health, shorten your life, and even cause death.

According to World Health Organization's (WHO), obesity has more than doubled since 1980

worldwide. Most of the world's population lives in countries where overweight and obesity kills more people than underweight. In India, about 11.2% of the population was found to be overweight or obese and more than 20% (do the math- 1 in 5) of urban Indians are overweight. Another population where obesity is increasing at an alarming rate is the pediatric population. To simply put obesity means having excess body fat; being overweight means having excessive weight for your height.

Body Mass Index (BMI) BMI is a useful measure of overweight and obesity. It is calculated from your height and weight. It may overestimate body fat in athletes and others who have a muscular build. • It may underestimate body fat in older persons and others who have lost muscle. •BMI Cut-offs for Asian Indians:

42 | January-February 2016 | Medical Device ASIA

Normal BMI: 18.0-22.9 kg/m2, Overweight: 23.0-24.9 kg/m2, Obesity: >25 kg/m2 BMIs for children and teens compare their heights and weights against growth charts that take age and sex into account. This is called BMI-for-age percentile. A child or teen's BMI-for-age percentile shows how his or her BMI compares with other boys and girls of the same age.

BMI-for-Age Percentile Interpretation Less than 5th percentile Underweight 5th percentile to less than the 85th percentileHealthy weight 85th percentile to less than the 95th percentileRisk of overweight 95th percentile or greater Overweight People gain weight due to bodies need calories (energy) to keep us alive and active. But to maintain weight we need to balance the energy we take in with the energy

we use. Simply stated calories in and calories out must be balanced.

When a person eats and drinks more calories than he or she burns, the energy balance tips toward weight gain, overweight, and obesity.

The tipping point at which the calories coming in and the calories going out become out of balance and lead to weight gain may differ from one person to another.

But it is not as simple as that. There are several other factors involved such as metabolism, genetic background, familial predisposition, dietary habits, medications (steroids and antidepressants for eg.), your own intestinal bacteria (surprise), endocrine diseases (thyroid, steroid excess), and lack of sleep are some of the reasons one tends to gain or fail to lose weight.

Health Risks Type 2 diabetes with all its complica-

tions, heart disease, high blood pressure, stroke, kidney disease, and certain cancers are some of the diseases linked to excess weight.

Obese men are more likely than other men to develop cancer of the colon, rectum, or prostate. Obese women are more likely than other women to develop cancer of the breast (after menopause), gallbladder, uterus, or cervix. Cancer of the esophagus (the tube that carries food and liquids to the stomach) may also be linked to obesity.

Other diseases and health problems linked to excess weight include • breathing problems, including sleep apnea • fatty liver disease (also called nonalcoholic steatohepatitis or NASH)

factors for a serious health condition.

Eat better Eating healthy foods has vital health benefits, kick starting your metabolism and promoting weight loss.

Portion control and caloric restriction is vital. Cutting back on calories (energy IN) will help you lose weight. To lose 0.3-0.5 kgs a week, adults should cut back their calorie intake by 500 to 1,000 calories a day.

We have to train our stomachs into getting used to frequent small meals.

A common mistake we make is to overdo something we believe is healthy. Those who eat kilos of fruits in a single day are bound to put on weight.

To start eating better, try these tips:

• gallbladder disease and gallstones • pregnancy problems, such as gestational diabetes (high blood sugar during pregnancy), high blood pressure, and increased risk for cesarean section (C-section) and infertility Most adults don't need to see their doctor before starting a physical activity program. However, those who should see a doctor include men older than 40 and women older than 50 who plan a vigorous program or who have either a serious health condition or risk

• Eat the rainbow. Make half of what's on your plate fruit and vegetables.

• Replace refined grains with whole grains, like oatmeal, whole wheat bread, and brown rice.

water.

• For metabolism boosting foods, try papaya (4-5 pieces), apples (1/2), banana (1), flaxseed with yoghurt, 4-5 pieces of nuts (almonds, pistachios), oats, quinoa, ragi, bajra, and cracked wheat.

• The Indian diet is loaded with carbs. To restrict it is the first change you need to make. Don’t cut out fat altogether. Your body needs good fat to regulate hormones. Two teaspoons of ghee, olive oil and a small cube of cheese can meet this requirement.

• Get your protein from healthy sources, like seafood, lean meats, poultry, eggs, beans, unsalted nuts, and seeds.

A little goes a long way; fortunately, losing even a small amount of weight can help improve your health. This weight loss may lower your blood pressure and improve other risk factors. For example, research shows that people at high risk for type 2 diabetes who lose a modest amount of weight and increase their physical activity may prevent or delay type 2 diabetes.

Remember, weight control is a lifelong effort- so make the journey enjoyable!! Here's to better health.

• Instead of sugary drinks, choose unsweetened tea, low-fat milk, or

By Dr. Rucha Mehta, Head, Department of Endocrinology, Diabetes, Obesity and Metabolism, Global Hospitals, Mumbai

Medical Device ASIA | January-February 2016 | 43

• Need for medical clearance before a marathon?

• What are the risks associated with a Marathon?

1. General Body CheckTest Name: CBC- To check anaemia, infection and measure cell count of various blood components.

Result: Good haemoglobin levels are very important for marathon runners.

2. Diabetes Check Test Name: HBA1c, Glucose Fasting, D3 Hydroxy Butarate.

Result: Endurance training lowers blood sugar. May lead to diabetic ketoacidosis which is life-threatening. The above tests will help diabetics plan their insulin doses and also screen general mass of diabetes.

3. Cardiac Check A. Test Name: Lipid Profile Mini, CPKTotal, Stress test, ECG, Blood

Pressure.

Result: High levels of HDL cholesterol are generally observed in endurance / marathon trainers. HDL facilitates fibrinolysis and prevents the occurrence of coronary heart disease. Abnormally high levels of LDL may require further testing before the run.

B. Test Name: CPK Result: High CPK suggests muscle / heart / brain injury which may be aggravated because of endurance training. Hence it becomes important to monitor CPK. C. Test Name: ECG/Stress Test Result: Important test to monitor the functioning of heart in order to prevent sudden heart failure post marathon.

4. Bone Health Check Test Name: Calcium / Vit D Result: People with low calcium and Vit D are more prone to ligament / muscular/ bone injuries. Such deficiencies prolong the process of

healing of injuries.

5. Kidney Health Check Test Name: Kidney Function Test Result: Kidneys help regulate blood pressure and plays a vital role in the production of RBCs. Normal kidneys is required for high level endurance training.

6. Liver Health CheckTest Name: Liver function Test Result: Liver plays a vital role in digestion, metabolism and detoxification. Hence it is important to monitor this organ before a marathon as during the run large toxins are produced in the body.

Speaking on the launch, Dr Nilesh Shah, Group President & SBU Head, West India, Metropolis Healthcare said, “We have seen and heard of instances where athletes collapse during marathon due to sudden cardiac arrest or shooting up of blood pressure etc. The body undergoes various changes with the age and one must not take it for granted; a thorough check-up should be carried out before undertaking any such activity under the supervision of a qualified physician and one should also understand one’s physical limitation.

Nothing is more precious than life.

Also patients suffering from asthma, lung or kidney issues, diabetes should be extremely cautious before undertaking the marathon.”

With the huge growing popularity of marathon running, it's important to make sure that the body is up for the challenge. Getting acquainted of personal health records, heart rate and blood sugar level, is the best way to safeguard long-term health issues by classifying troublesome concerns at the earliest.

About Metropolis Healthcare Ltd

44 | January-February 2016 | Medical Device ASIA

At Metropolis, what we believe is what we say and what we say is what we do. Being empathetic to our customers and being committed to their needs is in our DNA. Metropolis has grown to harness a culture that is open, synergistic, progressive and scientific in nature.

We are the Pathology Specialists delivering over 30 million tests a year, catering to more than 10,000 Laboratories, Hospitals, Nursing homes and 2,00,000 Consultants.

With 34 years of experience in delivering accurate reports, Metropolis has earned the reputation of being India's most respected and only multinational chain of diagnostic centers with presence in UAE, Sri Lanka, South Africa, Kenya, Mauritius and Ghana.

Driven to make a difference, our wide network includes 130 state-ofart Laboratories across India with over 1000 collection centers, processing over 4500 varieties of tests and supported by an efficient team of more than 3500 people.

Equipped with cutting edge technology, innovative work equipment, expansive logistics network and rigorous processes, Metropolis ensures and delivers precision and accuracy in every single test; each time, every time.

In the last 10 years, Metropolis has expanded into new service lines like Clinical Trials, Hospital Lab Management, Home Health Services, Preventive Health Check-ups and Corporate & Wellness Solutions.

Metropolis is at the forefront in adopting cutting edge technologies and services that contribute new revenue streams and has positioned the company on the pedestal it is today.

Today, we are one of the few laboratories that has received the CAP (College of American Patholo-

gists), accreditation, the global gold standard in Laboratory Accreditation.

We have also received the NABL Accreditation (National Accreditation Board for testing and Calibration Laboratories). In addition, we also adhere to CLIA (Clinical Laboratory Improvement Amendments) program and follow the guidelines laid by GCP and GLP. Our unit in South Africa is accredited by SANAS (South African National Accreditation System is the only accreditation body approved by South African Government).

At Metropolis, we believe in unveiling the inner health of individuals and this motto extends to our corporate social responsibility activities as well.

Giving back to the society is embedded in the value system of Metropolis and we believe and aim

to bring about a positive change in the nation. Metropolis has been at the forefront in conducting impactful camps and driving numerous workshops for different sections of the society for the past 3 decades.

We partner with societies, corporates, educational institutions, government bodies, NGOs, wellness foundations and a host of other organisations to make a difference to the lives we touch.

Our camps and awareness workshops emphasize on preventive healthcare and early screening of diseases. Some of our most recent associations include Epilepsy Foundation, Hep Free India, Mumbai Traffic Police, Kishori Foundation, Children of Blind School and JeevanJyot Cancer Trust.

Metropolis has been awarded numerous accolades like the ‘Best

Diagnostic Company of the year’ by Modern Medicare in 2006 and ‘Best Diagnostic Company of the Year’ in 2010 by Frost & Sullivan. Metropolis was also bestowed with ‘Best IT Integration in Customer Service Management’ at the e-Health World Expo 2011. Metropolis was also honoured with the ‘Quality Brand Award’ by NEHRDO in 2012.

Metropolis won the ‘CMO Asia Award’ for Best IT practices in Healthcare in 2012. Metropolis recently bagged the ‘India’s most promising brand award’ at Global Indian Excellence Summit 2014 held in London.

Metropolis Healthcare is led by Ameera Shah, Managing Director & CEO. An International & National Award winner, she was conferred with ‘The Young entrepreneur of the Year Award’ by GE in 2006 and ‘The

Young Achiever of the Year Award’ at the CMO Asia Awards in 2011.

She was also the recipient of the prestigious ‘Young Entrepreneur of the Year Award’ in 2011 organised

by Entrepreneur India and Bloomberg. She has been honoured with ‘Exemplary Women Leadership award’ at the World Women Leadership and Congress awards 2014. Recently she has been chosen as one of the most respected leaders under 40 years by Economic Times & Spencer Stuart (2014). Metropolis recently being awarded “Diagnostic Services Company of the year” at Vccircle Healthcare awards 2015.

For more information please contact: Rahul Lakhpati : +91 9819225352 @ rahul.lakhpati@bluelotuspr.com Reema Chaurasia : +91 8087843256 reema.chaurasia@bluelotuspr.com

Medical Device ASIA | January-February 2016 | 45

Aptar Stelmi features PremiumCoat™ at CPhI India ON DECEMBER 1-3, 2015, IN MUMBAI APTAR STELMI HALL #1 – BOOTH# F30

our range of innovative solutions for high-value injectable drugs,” said Ghislain Fournier, Industrial & Technical Director, Aptar Stelmi.

About Aptar Stelmi

Coated stoppers for sensitive and high-value injectables Aptar Stelmi, the industry’s trusted global partner, providing premium elastomeric closure systems for injectables, announces a new addition to its broad portfolio of products with the introduction of a novel range of coated stoppers called PremiumCoat™, designed for the protection of sensitive and highvalue drugs, including biopharmaceuticals.

Sensitive and high-value injectables, a dynamic market Sensitive and high-value injectables encompass complex and potent drugs manufactured by chemical synthesis and biological agents engineered in a living system such as a microorganism, plant or animal cell.

They include cytotoxic drugs used in cancer therapies, novel vaccines,

blood derivatives, hormones and many compounds used to treat auto-immune diseases, including monoclonal antibodies.

The market for biologics represents 20% of the global drug market with growth at a CAGR of 10% in 20102015, twice that of the global drug market.

Sensitive and high-value injectables require premium components Sensitive and high-value injectables are fragile by nature. Therefore maintaining the integrity of the container closure while minimizing interaction between the drug compound(s) and the component constituents is a challenge.

Conventional elastomeric closure systems may not be an optimal solution for these fragile drugs.

46 | January-February 2016 | Medical Device ASIA

PremiumCoat™ is a novel range of elastomeric stoppers developed by Aptar Stelmi. The surface of the elastomer is coated during manufacturing with a thin fluoropolymer film.

This coating acts as an effective barrier to many of the extractables and leachables that can be released from the elastomer and contaminate the drug. As a result, compatibility of the drug and the closure is significantly superior with PremiumCoat™ stoppers.

“Aptar Stelmi is looking forward to presenting PremiumCoat™ at the upcoming CPHI India in December 2015.

The past three years we have spent developing the technology and then preparing for this new product launch have been very exciting.

PremiumCoat™ is the first product in

Part of the Pharma division of AptarGroup, Inc., Aptar Stelmi is a trusted partner of leading pharmaceutical companies in the design and manufacturing of elastomeric closures for parenteral applications.

Driven by quality, service, and innovation for more than 50 years, Aptar Stelmi products meet the evolving drug industry demands for cleanliness, efficiency and compliance.

Our pre-filled syringe components and stoppers for vials are used to multiple applications in more than 70 countries worldwide.

AptarGroup, Inc. (NYSE: ATR) is a leading global supplier of a broad range of innovative dispensing systems for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets.

AptarGroup is headquartered in Crystal Lake, Illinois, with manufacturing facilities in North America, Europe, Asia and Latin America.

For further information, visit www.aptarstelmi.com

Metropolis Healthcare launches ‘The Marathon’ Health Check –up Package

diagnostic initiative will be available across Metropolis centers in Mumbai.

Metropolis Healthcare Ltd, The Pathology Specialist has launched ‘The Metropolis Marathon Package’ a comprehensive diagnostic package comprising 20 distinct tests to screen the complete health of a marathoner. The first of its kind

The sheer number of Indian runners participating in marathons continues to grow and new half marathons and full marathons are being added every year. Marathon is considered as the ultimate running challenge and marathon enthusiasts train for over a year before the grand finale. Training for a marathon can be just as strenuous as running a marathon. It is important to understand that running

for 42kms (full marathon) or 21kms (half-marathon) needs a different conditioning for the body and muscles.

‘The Metropolis Marathon Package’ is a comprehensive health package comprising a group of tests to screen the complete health of individuals taking part in the marathon which includes an indepth cardiac risk analysis and an overall assessment of kidney and liver function. Whether you are a novice or a seasoned marathon

runner, it is important to know your physical limits and capabilities.

Prolong running may cause difficulties to heart in refilling chambers and abnormalities in pumping blood from the right side of the heart to the lungs.

Health checks every runner must undergo • Are you fit enough to run a Marathon?

• Do you have a family history of Diabetes/Blood pressure/Heart Attack?

Medical Device ASIA | January-February 2016 | 47

7 out of every 10 Indians are Vitamin deficient: Metropolis Study

P

an India study of 14,96,683 samples reveals alarming statistics Mumbai, 13th October, 2015: Metropolis Healthcare – a multinational chain of diagnostic centres conducted an inclusive study on Vitamin D, Vitamin B12 and Vitamin B9 (Folic Acid) to observe the deficiency and sufficiency of Vitamins within the inhabitants across India. Metropolis conducted a comprehensive pan India study on 14,96,683 samples over a period of 3 years. The increasing trend of Vitamin deficiency is seen in all the age groups. Among the samples tested across 4 zones viz, North, South, East, West 75% of population has shown alarming levels of deficiency.

Commenting on the study Dr. Sonali Kolte, General Manager, Medico Marketing said, “Indians have a lethargic attitude towards Vitamins.

Vitamin deficiencies usually develop slowly over several months to years.

Symptoms of Vitamin D deficiency are usually vague muscle/joint pain, weakness, bone pain, tiredness, fatigue or even depression.

Nowadays it is observed that people who are deficient in Vitamin D are more likely to have diabetes, regardless of how much they weigh.

Early diagnosis and treatment can help control the symptoms and prevent health related problems.”

The Study In an analysis of over 14, 96,683 patients who underwent Vitamin tests, the following trends emerged.

• 81.28% of all samples tested were deficient in Vitamin D • 21.02% of all samples tested were deficient in Vitamin B12 • 15.06% of all samples tested were deficient in Vitamin B9 Vitamin D: It has been a general belief that vitamin D deficiency is uncommon in India because of abundant sunshine. There is,

Gender wise patterns emerged as below Zone Male Female Average Vitamin D Deficiency North Zone 81.41% East Zone 85.10% West Zone 82.06% South Zone 81.27%

75.97% 83.23% 78.54% 82.67%

78.69% 84.17% 80.30% 81.97%

Vitamin B12 Deficiency North Zone 29.70% East Zone 22.94% West Zone 23.89% South Zone 23.74%

23.53% 21.05% 15.43% 7.90%

26.62% 22.00% 19.66% 15.82%

Vitamin B9 Deficiency North Zone 15.53% East Zone 16.28% West Zone 17.51% South Zone 29.33%

9.36% 13.23% 9.25% 10%

12.45% 14.76% 13.38% 19.67%

48 | January-February 2016 | Medical Device ASIA

AGE GROUP WISE DEFICIENCY OF VITAMIN D IN BELOW TABLE Vitamin D 1 to 20 Deficiency Sufficiency Grand Total % of Deficiency

20 to 40 23376 5399 28775 81.24

40 to 60 96268 19019 115287 83.50

however, now increasing evidence that this is not true. Vitamin D deficiency has reached epidemic proportions in India despite ample sunshine.Vitamin D is unique because it is a vitamin synthesized by the body and it functions as a hormone.

Vitamin D is important for overall good health and strong and healthy bones. It’s also an important factor in making sure your muscles, heart, lungs and brain work well and that your body can fight infection. Your body can make its own vitamin D

60 to 80 & Above 94926 240540 29321 74010 124247 314550 76.40 76.47

from sunlight. You can also get vitamin D from supplements and a very small amount comes from a few foods you eat. They are vital for everyone and ensure that your body works well and is able to fight illness and heal well. Vitamin D manages calcium in your blood, bones and gut and helps cells all over your body to communicate properly.

Most common reason to have deficient levels of vitamin D is due to limited sunshine exposure.

Studies suggest that vitamin sufficiency may even help ease

AGE GROUP WISE DEFICIENCY OF VITAMIN B12 IN BELOW TABLE Vitamin B12 Deficiency Sufficiency Grand Total % of Deficiency

1 to 20 5924 23639 29563 20.04

20 to 40 41344 149393 190737 21.68

fibromyalgia pain and slow the progression of multiple sclerosis.Vitamin Deficiency has also been linked to the various serious health conditions such as dementia, Alzheimer’s disease, prostate cancer, erectile dysfunction and mental disorder such as Schizophrenia.

Vitamin B12 regulates the functions of the brain and nervous system. It also plays an important role in the formation of blood. Some of the common symptoms of vitamin B12 deficiency are weakness, apathy, memory loss, acidity, loss of weight, nausea and vomiting, anemia, mental confusion, delusions, paranoia, respiratory symptoms, hives and other symptoms of allergy. A longterm deficiency can lead to heart attacks or stroke. The important sources of Vitamin B12 are mostly animal products like meat, fish, poultry, eggs and also dairy items.

Pure vegetarian diet may result in Vitamin B12 deficiency which is becoming common amongst Indians.

Vitamin B12 is also used to treat memory loss; Alzheimer’s disease; boosting mood, energy, concentration and the immune system; and slowing aging. Vitamin B12 also helps our bodies absorb folic acid, which facilitates the release of energy. The risk of B12 deficiency increases along with your age.

Elderly people with low-vitamin B12 are more likely to suffer from brain shrinkage and cognitive decline.

40 to 60 31359 136627 167986 18.67

60 to 80 & Above 85619 380571 466190 18.37

Vitamin B9, more commonly known as folate or folic acid, is a watersoluble vitamin that is part of the B vitamin family. Vitamin B9 (folic acid) is vital for several bodily functions, such as synthesis of DNA, RNA, to repairaiding rapid cell division and growth, to produce healthy red blood cells. It is important for pregnant women to have enough folic acid to prevent major birth defects of her baby's brain or spine (neural tube defects, including spina bifida and anencephaly). It enhances brain health, folic acid supplementation may improve memory.

Vitamins Deficiency is prevalent across India. Our pan India study also indicated that the majority of the study participants had limited knowledge, poor practices, and an ignorant attitude towards vitamin sufficiency. Clear messages are needed about risks and benefits of vitamins. If you're unsure if you're getting an adequate amount of vitamins, consult with your doctor.

About Metropolis Healthcare Ltd At Metropolis, what we believe is what we say and what we say is what we do. Being empathetic to our customers and being committed to their needs is in our DNA. Metropolis has grown to harness a culture that is open, synergistic, progressive and scientific in nature.

We are the Pathology Specialists delivering over 15 million tests a year, catering to more than 10,000 Laboratories, Hospitals, Nursing homes and 2,00,000 Consultants.

With 34 years of experience in

AGE GROUP WISE DEFICIENCY OF VITAMIN B9 IN BELOW TABLE Vitamin B9 Deficiency Sufficiency Grand Total % of Deficiency

1 to 20 770 3454 4224 18.23

20 to 40 4574 14075 18649 24.53

40 to 60 3145 12350 15495 20.30

60 to 80 & Above 1846 19134 20980 8.80

delivering accurate reports, Metropolis has earned the reputation of being India's most respected and only multinational chain of diagnostic centers with presence in UAE, Sri Lanka, South Africa, Kenya, Mauritius and Ghana.

Driven to make a difference, our wide network includes 125 state-ofart Laboratories across India with over 800 collection centers, processing over 4500 varieties of tests and supported by an efficient team of more than 3500 people.

Equipped with cutting edge technology, innovative work equipment, expansive logistics network and rigorous processes, Metropolis ensures and delivers precision and accuracy in every single test; each time, every time.

In the last 10 years, Metropolis has expanded into new service lines like Clinical Trials, Hospital Lab Management, Home Health Services, Preventive Health Check-ups and Corporate & Wellness Solutions.

Metropolis is at the forefront in adopting cutting edge technologies and services that contribute new revenue streams and has positioned the company on the pedestal it is today.

Today, we are one of the few laboratories that has received the CAP (College of American Pathologists), accreditation, the global gold standard in Laboratory Accreditation.

We have also received the NABL Accreditation (National Accreditation Board for testing and Calibration Laboratories). In addition, we also adhere to CLIA (Clinical Laboratory Improvement Amendments) program and follow the guidelines laid by GCP and GLP. Our unit in South Africa is accredited by SANAS (South African National Accreditation System is the only accreditation body approved by South African Government).

At Metropolis, we believe in unveiling the inner health of individuals and this motto extends to our corporate social responsibility activities as well. Giving back to the society is embedded in the value system of Metropolis and we believe and aim to bring about a positive change in the nation.

Metropolis has been at the forefront in conducting impactful camps and driving numerous workshops for different sections of the society for the past 3 decades. We partner with societies, corporates, educational institutions, government bodies, NGOs, wellness foundations and a host of other organisations to make a difference to the lives we touch.

Our camps and awareness workshops emphasize on preventive healthcare and early screening of diseases.

Some of our most recent associations include Epilepsy Foundation, Hep Free India, Mumbai Traffic Police, Kishori Foundation, Children of Blind School and JeevanJyot Cancer Trust. Metropolis has been awarded numerous accolades like the ‘Best Diagnostic Company of the year’ by Modern Medicare in 2006 and ‘Best Diagnostic Company of the Year’ in 2010 by Frost & Sullivan.

Metropolis was also bestowed with ‘Best IT Integration in Customer Service Management’ at the e-Health World Expo 2011. Metropolis was also honoured with the ‘Quality Brand Award’ by NEHRDO in 2012.

Metropolis won the ‘CMO Asia Award’ for Best IT practices in Healthcare in 2012. Metropolis recently bagged the ‘India’s most promising brand award’ at Global Indian Excellence Summit 2014 held in London.

Metropolis Healthcare is led by Ameera Shah, Managing Director & CEO. An International & National Award winner, she was conferred with ‘The Young entrepreneur of the Year Award’ by GE in 2006 and ‘The Young Achiever of the Year Award’ at the CMO Asia Awards in 2011.

She was also the recipient of the prestigious ‘Young Entrepreneur of the Year Award’ in 2011 organised

by Entrepreneur India and Bloomberg. She has been honoured with ‘Exemplary Women Leadership award’ at the World Women Leadership and Congress awards 2014. Recently she has been chosen as one of the most respected leaders under 40 years by Economic Times & Spencer Stuart (2014).

Medical Device ASIA | January-February 2016 | 49

DR MUKESH BATRA AWARDED THE PRESTIGIOUS ‘THE LIFETIME ACHIEVEMENT AWARD’ FOR HIS PATH BREAKING WORK IN THE FIELD OF HOMEOPATHY MEDICINE

D

r Mukesh Batra, Padma Shri Recipient, a visionary entrepreneur with professional excellence and experience of over 40 years in the field of Homeopathy has been honoured with Rotary Club’s ‘The Lifetime Achievement Award’ for his path breaking work in the field of homeopathy medicine during an award ceremony held in Mumbai.

The award was presented by DGE Gopal Rai Mandhania in the presence leaders in healthcare and some well known celebrities like Mandira Bedi, Raageshwari and Samir Mondal at a glittering award function.

responsible for pioneering modern Homeopathy in India; he has not only set up a colossal corporate empire but also extended the medical benefits of this safe and sure medical system to all through path-breaking initiatives.

Dr Batra has been single-handedly

Accepting the award, Dr Mukesh

Dr Batra has strived incessantly to bring about the acceptance and legalization of Homeopathy across the world and was instrumental in legalizing the science in Mauritius where he set up its first homeopathic clinic. He successfully introduced Homeopathy to the Middle East countries.

50 | January-February 2016 | Medical Device ASIA

Batra, Padma Shri recipient, FounderChairman of Dr Batra's Group of companies said, "I feel honoured and humbled to receive this recognition for my efforts to promote homeopathy. Such recognition makes me believe that if one has the right vision and aim, one can achieve anything possible.

Today homeopathy is viewed as a modern, progressive, efficient and

effective medical option and standardised homeopathic treatment is available all around the country. The journey for me has been challenging yet fulfilling. The core belief on which I have built my company is to provide health and wellness to those in need, through cost-effective and safe homeopathy, along with the best of scientific and technological advancements."

Bosch at Gulfood Manufacturing 2015 New Pack 301 LS system to meet growing demand for flow wrapped biscuits on edge“Designed for flexible packaging and high product quality.

I

nnovative full-servo product transfer for gentle handling“Easy access, cleaning and maintenance“Suitable for a wide range of product shapes and slug lengths“Dubai, United Arab Emirates – At Gulfood Manufacturing 2015, Bosch Packaging Technology presented its Pack 301 LS (Length Slug) system for the efficient and flexible packaging of biscuits and crackers on edge.

The packaging machine has been developed as an addition to the Pack Series of horizontal flow wrappers, which range from entrylevel models to fully automated technologies. It is designed to help manufacturers meet the increasing market demand for biscuit wrapping together with premium product quality.

At the show, the packaging solution was manually loaded and comprised of a Smart Slug Feeder as well as the Pack 301 LS horizontal flow wrapper. For automated loading, Bosch’s Smart Measuring Loader can be easily integrated in the system.

With innovative features for gentle product handling, as well as fast and simple changeovers, all components have been developed with a holistic approach and for high reliability and robustness.

Working closely with our customers in the Middle East, we are seeing increasing demand for full-line automation to address growing market needs and evolving consumer demands,” says Feyssal Omar, regional sales director, Middle East and North Africa, Bosch Packaging Technology. “To enable Middle Eastern biscuit producers to get ahead of the competition and enhance flexibility, we have developed the Pack 301 LS. Its highly versatile layout configuration, fast changeovers and easy maintenance help bakery manufacturers increase adaptability and enhance their competitive advantage.

Innovative features for reliable product handling The Pack 301 LS system including the Smart Measuring Loader for slug

portioning has been designed specifically to ensure gentle product handling for delicate and brittle biscuit-type products – even at higher speeds. Transfer points from the loader to the cross chain, from the cross chain to the infeed chain and further into the film tube generally pose the greatest risk for product damage and breakage.

Due to the full-servo execution, the Smart Measuring Loader allows for smooth placement of the portioned biscuits into the cross chain. The Smart Transfer Unit features preacceleration for optimal synchronization with the infeed chain. It therefore eliminates impact on the product when bringing it from the cross chain into the machine infeed, ensuring gentle, reliable handling.

To keep the biscuits in an upright position while being transported into the film tube the biscuit portion is supported by a counter holding pin. The position where the counter holding pin comes up can be easily modified by the operator via an adjusting knob. Between the folding

box and the cross-sealing station the slug is guided carefully by side belts or chains towards the crosssealing station.

Depending on the product characteristics, operators can easily exchange side belts with side chains and vice versa for enhanced flexibility and optimal support. All of these innovative features ensure that products are kept under control during the complete packaging process. Additionally, the narrow design of the cutting head improves sealing performance and creates tight seals.

Total Productive Maintenance Designed with the operators and Total Productive Maintenance in mind, the solution has been laid out to be accessed from all sides for smooth operation, fast and easy cleaning, and low maintenance effort. The cross chain features a spring loaded chain tensioner with visual feedback, allowing the operator to easily check whether there is optimal chain tension or it should be adjusted. Machine parts

Medical Device ASIA | January-February 2016 | 51

in contact with the product are made of stainless steel, meeting today’s hygienic standards. The open design allows crumbs and rejected products to fall through or be removed easily.

Thanks to optimized interfaces, the integrated system can be provided with all required upstream equipment including vibratory channels, offering a complete solution from a single supplier.

All of these features add to operator friendliness and boost machine uptime and availability.

Flexibility for product shapes and lay-out configurations

A holistic approach for maximized Overall Equipment Effectiveness All aspects of the Pack 301 LS are designed to minimize downtime and enable stable output at high production speeds. To increase Overall Equipment Effectiveness (OEE), the complete biscuit feeding and packaging solution is operated by a single HMI, which enhances fast changeovers for different formats and sizes. In addition, whenever a product is missing, the “no product – no cycle” option stops both the infeed and the machine when a product is missing to avoid empty packages.

Developed to address current and future market requirements, the Pack 301 LS system is capable of packaging rectangular, square and round products, as well as sandwich biscuits.

Depending on the manufacturer’s requirements, the solution can be equipped with up to ten vibratory channels. The modular design allows for scalable solutions and layout flexibility, enabling manufacturers to easily expand their production capacity or increase the level of automation from entry level, hand fed machines to fully automated solutions. The Pack 301 LS system was displayed at Gulfood Manufacturing in Dubai World Trade

52 | January-February 2016 | Medical Device ASIA

Centre in Dubai, UAE, held from October 27 to 29.

Based in Waiblingen near Stuttgart, Germany, and employing 6,100 associates, the Bosch Packaging Technology division is one of the leading suppliers of process and packaging technology. At over 30 locations in more than 15 countries worldwide, a highly-qualified workforce develops and produces complete solutions for the pharmaceuticals, food, and confectionery industries.

These solutions are complemented by a comprehensive after-sales service portfolio. A global service and sales network provides customers with local points of contact. Additional information is available online at www.boschpackaging.com The Bosch Group is a leading global supplier of technology and services.

The company employs roughly 360,000 associates worldwide (as per April 1, 2015), and generated

sales of 49 billion euros in 2014.* Its operations are divided into four business sectors: Mobility Solutions, Industrial Technology, Consumer Goods, and Energy and Building Technology.

The Bosch Group comprises Robert Bosch GmbH and its roughly 440 subsidiary and regional companies in some 60 countries. Including its sales and service partners, Bosch is represented in roughly 150 countries. This worldwide development, manufacturing, and sales network is the foundation for further growth. In 2014, Bosch applied for some 4,600 patents worldwide.

The Bosch Group’s strategic objective is to create solutions for a connected life. Bosch improves quality of life worldwide with products and services that are innovative and spark enthusiasm. In short, Bosch creates technology that is “Invented for life. Additional information is available online at www.bosch.com, www.boschpress.com.

MACOR® Glass Ceramic: Enabling Medical Industry Innovation soft metals. This allows manufacturers to develop the calibre components required in high performance medical devices, meeting the industry’s demands for quality and reliability.

HIGH TENSILE STRENGTH

M

ACOR® machinable mica glass ceramic material is recognized around the world as an outstanding engineering solution, which can be used by manufacturers to create lightweight, precision components for use in high-performance medical and laboratory technologies, as well as equipment for a host of other sectors.

Offering the strength and durability of a technical ceramic, the versatility of a high-performance polymer and the machinability of a soft metal, MACOR® can be used to design components with complex geometries for use in medical equipment, such as blood glucose monitors and blood pressure meters, and laboratory devices quickly and simply by using conventional metalworking tools.

MACOR® and the Medical Industry With an ageing worldwide population, growing prevalence of chronic diseases, and rising healthcare costs, there is increasing global demand for more cost-effective medical devices. At the same time, though, manufacturers have to ensure that their products offer exceptional reliability, high performance and additional features, all in a smaller package to ensure devices are able to fit in increasingly crowded operating rooms.

MACOR® is able to hold tolerances of as little as 0.0005 inches, and can be machined to a surface finish of just 20 micro inches, with a smoothness of 0.5 micro inches AA, enabling the creation of precision components that keep performance and reliability required by the medical profession. This, combined with the material’s high rigidity, means that components can be made using a fraction of the material that would be needed using traditional solutions and at a reduced size, lowering production costs and supporting manufacturers in meeting their medical device miniaturization goals.

With its high temperature resistance, exceptional tensile strength, insulation properties and resistance to radiation, MACOR® enables the manufacture of precision components with complex shapes to maximize device performance.

STANDING THE HEAT As the graph shows, MACOR® has a low expansion in high-temperature conditions, allowing it offer consistent performance during operation. This, along with its easy machinability during manufacture, ensures MACOR® can hold exceptionally tight tolerances of as little as 0.0005 inches, providing higher precision than polymers or

In laboratory tests, MACOR® has demonstrated a high Young’s Modulus – or rigidity – even at high temperatures. This means that components manufactured from the substance remain rigid under strain, even in harsh operating conditions, such as those experienced within medical electronic devices when they have been left on for extended periods. As a result, MACOR® parts can be made using less material than those manufactured with traditional substances, allowing manufacturers to reduce production costs to protect profit margins, and to produce smaller components to reduce the overall size of the finished medical or laboratory device.

A SOLID GLASS FOUNDATION FOR YOUR INVENTIONS MACOR® has a continuous use temperature of 800°C, and a peak temperature of 1000°C. Its coefficient of thermal expansion matches most metals and sealing glasses, meaning it can perform in harsh operating environments where precision is a necessity. In addition to its precision and rigidity, MACOR® also offers a host of other properties that make it ideal for use in a broad range of demanding medical and laboratory applications.

• Fast turnaround, no post firing required • Holds tight tolerances, as low as .0005 inches • Clean, no outgassing and zero porosity • Won’t deform, unlike ductile materials • Has low thermal conductivity, is an excellent electrical insulator • Radiation resistant • Improved wear and insulation properties make MACOR® a suitable alternative material to plastics • Can be soldered – both to itself and to a wide range of materials What can MACOR® do for you?

There are any number of applications in the medical and laboratory sectors making use of MACOR® manufactured components, with new uses being found and developed every day in technologies including: • Blood glucose monitors • Blood pressure meters • X-ray scanner/ nuclear PET scanner • And many other specific components If you are interested in versatile and high-performance materials to fulfill your designs, then MACOR® can help. To find out how MACOR® can benefit your medical applications, please contact us: Corning Contact: Franck de Lorgeril Global Marketing and Sales Manager Industrial Products CORNING Specialty Glass +33(0)1 64 69 70 39 +33(0)6 81 58 66 94

BENEFITS AT A GLANCE: • Easily machinable using conventional metalworking tools • Machinability to a surface finish of less than 20 micro-inches and to a smoothness of 0.5 micro-inches AA

Email: DeLorgerF@corning.com Website: www.corning.com For more information about Corning, please visit : www.corning.com/

Medical Device ASIA | January-February 2016 | 53

TECHNICAL CERAMICS EMPOWER MEDICAL AND DENTAL ADVANCEMENTS

Benefits of technical ceramics drive increased demand for product globally

by Geoff Randle, Director, Precision Ceramics

I

n many ways, material science is driving enormous and exciting change for the medical community. Technical advancements, new applications and product innovations are empowering industry growth and influencing new global market trends. Novel biocompatible materials for sensors, delivery systems, imaging and screening devices mean that companies are identifying new ways of improving disease detection and treatment.

The full spectrum of ceramic materials, nitrides, oxides and carbides are increasingly used in these extremely demanding environments and are at the cutting edge of some of the latest advancements in the industries.

Reports in 2011 estimated the global medical ceramics market at $10.4 billion will reach $13.1 billion by 2017 . This has shown no sign of abating as market reports continue to demonstrate this upward trend .

Advanced ceramics offer a costeffective and high-performance substitute to traditional materials such as, metals and plastics. A large part of this development in the medical sector is implantable applications such as artificial joints, electronic sensors and drug delivery devices. There is also much development in the use of ceramics for dental implants.

MANUFACTURING APPLICATIONS Modern manufacturing has created production output capabilities that are simply phenomenal and demand repeatable performance, long life and sterility in the production process. One example of a modern automated process is volumetric filling systems, which fill containers and vials of drugs and over-thecounter pharmaceuticals. When

glass ampules are being filled with drugs, pumps and pistons are used to measure a defined amount of liquid into the container.

Ceramics have a vital role to play in the machinery as they have a longer life than other alternative materials, such as steel. The friction between the piston and the body of the pump can result in wear, which over a long life span, if using metal on metal, could result in powders or particulars breaking off. These could contaminate a whole production line, potentially resulting in huge financial losses for the manufacturer.

For this reason, advanced ceramics are a very popular choice by manufacturers due to their hard wearing and inert properties if they come in direct contact with drugs.

In addition, ceramics are a suitable material for the medical industry as they are easy to clean and keep sterile.

DENTAL APPLICATIONS Dental porcelain, either feldspathic or aluminous porcelain, used for crowns and incisors, has been the traditional application of ceramics in dentistry. Ceramics also have a wellestablished role in root canals as the material that bonds to the jawbone and holds the peg, which attaches to a crown. Europe is leading the global dental implant market with the largest share (41%), at an estimated $1,675.1 million in 2011 . The market offers tremendous growth potential, mainly due to the increasing demand, purchasing power, and consumer acceptance of advanced dental technologies in developing Asian and South American nations.

The trend towards high performance technical materials being used in dental procedures is another factor in the growth of the dental implants market, as they are robust proven

54 | January-February 2016 | Medical Device ASIA

materials. The introduction of computer-aided design/computeraided manufacturing (CAD/CAM) technology has also drastically reduced treatment time and costs.

Another innovative application that a manufacturer used ceramics for is the testing of dental drill bits.

Looking for a material that had similar properties to dentine (which is naturally found inside a tooth) and could be machined to high accuracy, the manufacturer selected MACOR® machinable glass ceramic.

As such, he could determine the optimum life cycle in accordance with different drill bit shapes.

MEDICAL APPLICATIONS Another area that ceramics have made inroads is blood dialysis equipment. Dialysis equipment and accessories, used for the artificial blood purification of end stage renal disease (ESRD) patients as well as acute kidney injury (AKI) patients, had a global market worth $13.4 billion in 2013 and expect to grow to $18.8 billion in 2018 due to a rising need for renal replacement and dialysis . Ceramics are used within the pumping systems of blood dialysis machines due to their performance as an inert material. It is the same material that is widely used in hip joint replacements. In addition to implant surgery and diagnostics, composites continue to gain recognition as a strong choice in prosthetics for artificial limbs and joints.

COSMETIC APPLICATIONS One of the fastest growing medical markets is for cosmetic treatments.

According to the International Society of Plastic and Aesthetic Surgeons (ISAPS), more than 23 million cosmetic procedures (surgical and non-surgical) were

performed worldwide in 2013.

Within cosmetics, light-based hair removal (LHR) is one of the fastest growing, nonsurgical aesthetic cosmetic procedures in the United States and Europe. IPL (Intense Pulsed Light) machines are used for a wide variety of dermatology applications involving broadspectrum intense pulsed light (IPL, 590–1200 nm). It is commonly used in the treatment of acne scars, rosacea, removing tattoos, scar removal and permanent hair removal.

As the machine is handheld, certain ceramics are highly suitable due to their low-density and they act as an effective thermal barrier. To create the light needed for the treatment, energy is absorbed by a coil enclosed in the main chamber of the machine. Multiple wavelengths are produced, with a specified amount of energy travelling from the device in the form of intense pulses of non-coherent light. A by-product of generating light is heat and to ensure that the heat from the coil does not melt, or heat the casing and potentially cause harm to the user, a ceramic that is a good electrical insulator is placed in the device to prevent electrical and thermal transfer. Across the globe, manufacturers improve the efficiency of their devices by adopting MACOR® glass ceramics to act as an electrical insulator and reduce thermal transfer.

Advanced ceramics are leading a new generation of medical and dental innovations worldwide. Their ability to offer cost-effective and yet high performance applications make them an exciting material.

MACOR® is a registered trademark of Corning Incorporated, Corning, NY.